%PDF-1.4%‚„œ”
62 0 obj
<</Metadata 64 0 R/PageLabels 8 0 R/Pages 57 0 R/Type/Catalog>>
endobj
64 0 obj
<</Length 1662/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 4.2.1-c043 52.389687, 2009/06/02-13:20:35        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/">
         <xmp:CreateDate>2013-02-05T16:00:19Z</xmp:CreateDate>
         <xmp:CreatorTool>QuarkXPress(tm) 6.5</xmp:CreatorTool>
         <xmp:ModifyDate>2015-05-25T05:40:51-07:00</xmp:ModifyDate>
         <xmp:MetadataDate>2015-05-25T05:40:51-07:00</xmp:MetadataDate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/">
         <pdf:Producer>QuarkXPress(tm) 6.5</pdf:Producer>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/">
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">Layout 1</rdf:li>
            </rdf:Alt>
         </dc:title>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdfx="http://ns.adobe.com/pdfx/1.3/">
         <pdfx:XPressPrivate>%%DocumentProcessColors: Black&#xA;%%EndComments</pdfx:XPressPrivate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/">
         <xmpMM:DocumentID>uuid:687fbf0f-1dd2-11b2-0a00-6708279d8f00</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:687fbf14-1dd2-11b2-0a00-14f600000000</xmpMM:InstanceID>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>
endstream
endobj
8 0 obj
<</Nums[0<</S/D>>]>>
endobj
57 0 obj
<</Count 4/Kids[58 0 R 59 0 R 60 0 R 61 0 R]/Type/Pages>>
endobj
58 0 obj
<</Annots 65 0 R/Contents 66 0 R/MediaBox[0 0 594 783]/Parent 57 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 67 0 R/GS2 68 0 R>>/Font<</T1_0 12 0 R/T1_1 16 0 R/T1_10 69 0 R/T1_2 20 0 R/T1_3 24 0 R/T1_4 28 0 R/T1_5 32 0 R/T1_6 36 0 R/T1_7 40 0 R/T1_8 44 0 R/T1_9 48 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
59 0 obj
<</Annots 70 0 R/Contents 71 0 R/MediaBox[0 0 594 783]/Parent 57 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 72 0 R/GS2 73 0 R>>/Font<</T1_0 16 0 R/T1_1 20 0 R/T1_2 36 0 R/T1_3 52 0 R/T1_4 32 0 R/T1_5 28 0 R/T1_6 56 0 R/T1_7 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
60 0 obj
<</Annots 74 0 R/Contents 75 0 R/MediaBox[0 0 594 783]/Parent 57 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 76 0 R/GS2 77 0 R>>/Font<</T1_0 16 0 R/T1_1 20 0 R/T1_2 36 0 R/T1_3 12 0 R/T1_4 40 0 R/T1_5 56 0 R/T1_6 28 0 R/T1_7 32 0 R/T1_8 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
61 0 obj
<</Annots 78 0 R/Contents 79 0 R/MediaBox[0 0 594 783]/Parent 57 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 80 0 R/GS2 81 0 R>>/Font<</T1_0 16 0 R/T1_1 20 0 R/T1_2 32 0 R/T1_3 28 0 R/T1_4 56 0 R/T1_5 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
78 0 obj
[82 0 R]
endobj
79 0 obj
<</Length 10129>>stream
1 g
/GS0 gs
0 783 0 0 re
f
0 0 0 0 k
/GS1 gs
50.5 312.558 493 420.635 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.006 Tc 0.006 Tw 8 0 0 8 50.5 727.7228 Tm
[(19.)-494 (Seeman P)110 (. An update of fast-)-75 (of)20 (f dopamine D)]TJ
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 5 0 0 5 206.5267 726.0727 Tm
(2)Tj
ET
BT
/T1_0 1 Tf
-0.006 Tc 0.006 Tw 8 0 0 8 210.996 727.7228 Tm
(atypical antipsychotics.)Tj
-0.02499 Tc 0.013 Tw -18.3745 -1.25 Td
[(Am J Psychiatry 2010;162:1984)-75 (-5.)]TJ
-0.01199 Tc 0.01199 Tw -1.6875 -1.375 Td
[(20.)-488 (Stahl SM. \322Hit-and-run\323 actions at dopamine receptors, part 1: mec\ha)-1 (-)]TJ
-0.03999 Tc 0.013 Tw 1.6875 -1.25 Td
[(nism of action of atypical antipsychotics. J Clin Psychiatry 2001;19:165\)-25 (-)-25 (8. )]TJ
-0.017 Tc 0.017 Tw -1.6875 -1.375 Td
[(21.)-483 (Li EC, Esterly JS, Pohl S, Scott SD, McBride BF)80 (. Drug-induced QT)90 (-)1 (i)1 (n)1 (-)]TJ
0 Tc 0.133 Tw 1.6875 -1.25 Td
[(terval prolongation: considerations for clinicians. Phar)-25 (macotherapy)]TJ
-0.02499 Tc 0 Tw 0 -1.25 TD
[(2010;30:684)-75 (-701.)]TJ
-0.00999 Tc 0.00999 Tw -1.6875 -1.375 Td
[(22.)-490 (Gupta A, Lawrence A)110 (T)76 (, Krishnan K, Kavinsky CJ, T)35 (rohman RG. Cur-)]TJ
-0.01199 Tc 0.01199 Tw 1.6875 -1.25 Td
(rent concepts in the mechanisms and management of drug-induced QT)Tj
-0.02499 Tc 0.013 Tw T*
[(prolongation and torsades de pointes. Am Heart J 2007;153:891)50 (-9.)]TJ
-0.021 Tc 0.021 Tw -1.6875 -1.375 Td
[(23.)-479 (Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.25 Td
[(fluoroquinolone therapy)65 (. Int J Antimicrob Agents 2007;29:374)-75 (-9.)]TJ
-0.005 Tc 0.005 Tw -1.6875 -1.375 Td
[(24.)-495 (V)109 (eiweg WV)130 (, W)80 (ood MA, Fer)-25 (nandez A, Beatty-Brooks M, Hasnain M,)]TJ
-0.011 Tc 0.011 Tw 1.6875 -1.25 Td
(Pangurangi AK. Proarrhythmic risk with antipsychotic and antidepres-)Tj
-0.02499 Tc 0.013 Tw T*
[(sant drugs: implications in the elderly)65 (. Drugs Aging 2009;26:997-1012.)]TJ
-0.005 Tc 0.005 Tw -1.6875 -1.375 Td
[(25.)-495 (M)1 (e)1 (y)1 (e)1 (r)21 (-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ.)]TJ
-0.02 Tc 0.02 Tw 1.6875 -1.25 Td
[(The FDA extended war)-25 (ning for intravenous haloperidol and torsades de)]TJ
-0.02499 Tc 0.013 Tw T*
[(pointes: how should institutions respond? J Hosp Med 2010;5:E8)-25 (-16.)]TJ
T*
(doi: 10.1002/jhm.691)Tj
0.02299 Tw -1.6875 -1.375 Td
[(26.)-475 (Harrigan EP)110 (, Miceli JJ, Anziano R, et al. A randomized evaluation of the)]TJ
0.002 Tw 1.6875 -1.25 Td
[(ef)20 (fects of six antipsychotic agents on QT)70 (c, in the absence and presence of)]TJ
0.013 Tw T*
[(metabolic inhibition. J Clin Psychophar)-25 (macol 2004;24:62-9.)]TJ
0 Tc 0.088 Tw -1.6875 -1.375 Td
[(27.)-500 (Psychophar)-25 (macological Drugs Advisory Committee. 19 July)65 (, 2000.)]TJ
0.05499 Tw 1.6875 -1.25 Td
(Briefing document for Zeldox capsules \(ziprasidone hydrochloride\).)Tj
-0.024 Tc 0.024 Tw T*
[(www)65 (.fda.gov/ohr)-25 (ms/dockets/ac/00/backgrd/3619b1.htm  \(accessed 2012)]TJ
-0.02499 Tc 0.013 Tw T*
(Jun 1\).)Tj
0 Tc 0.20399 Tw -1.6875 -1.375 Td
[(28.)-500 (Product infor)-25 (mation. Seroquel \(quetiapine\). W)40 (ilmington, DE: As-)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.25 Td
(traZeneca, July 201)Tj
0 Tw 7.37224 0 Td
(1.)Tj
-0.009 Tc -9.05974 -1.375 Td
(29.)Tj
0 Tc 1.71479 0 Td
(T)Tj
-0.009 Tc 0.009 Tw 0.53196 0 Td
(an HH, Hoppe J, Heard K. A systematic review of cardiovascular ef)Tj
0 Tc 26.73281 0 Td
(-)Tj
-0.02499 Tc 0.024 Tw -27.29206 -1.25001 Td
[(fects after atypical antipsychotic medication overdose. Am J Emer)20 (g Med)]TJ
0.013 Tw T*
(2009;27:607-16. doi: 10.1016/j.ajem.2008.04.020)Tj
-0.024 Tc 0 Tw -1.6875 -1.375 Td
(30.)Tj
0.024 Tw 1.65528 0 Td
(Lo B, Pizon A. Delayed presentation of an aripiprazole overdose \(letter\\).)Tj
-0.02499 Tc 0.013 Tw 0.03222 -1.25001 Td
[(Clin T)70 (oxicol \(Phila\) 2008;46:348)-25 (-9. doi: 10.1080/15563650701704859)]TJ
0 Tw -1.6875 -1.375 Td
(31.)Tj
0.002 Tw 1.64999 0 Td
[(Suzuki Y)130 (, Or)-25 (no S, Fukui N, et al. Dose-)-75 (dependent increase in the QT)70 (c in-)]TJ
-0.021 Tc 0.021 Tw 0.03751 -1.25001 Td
(terval in aripiprazole treatment after risperidone \(letter\). Prog Neur\opsy-)Tj
-0.02499 Tc 0 Tw T*
(chophar)Tj
0.013 Tw 3.07035 0 Td
(macol Biol Psychiatry 201)Tj
0 Tw 10.01428 0 Td
[(1;35:643)-25 (-)-125 (4. )]TJ
0.013 Tw -13.08463 -1.25001 Td
(doi: 10.1016/j.pnpbp.2010.10.024)Tj
-0.022 Tc 0.022 Tw -1.6875 -1.375 Td
[(32.)-478 (Leo R, Razzini C, Di Lorenzo G, et al. Asymptomatic QT)70 (c prolongation)]TJ
-0.006 Tc 0.006 Tw 1.6875 -1.25 Td
(during coadministration of aripiprazole and haloperidol \(letter\). J Cl\in)Tj
-0.02499 Tc 0.013 Tw T*
[(Psychiatry 2008;62:327-)-25 (8. )]TJ
0.002 Tw 30.625 50.375 Td
[(33.)-475 (LoV)110 (ecchio F)80 (, W)80 (atts D, W)40 (inchell J. One-year experience with aripiprazole)]TJ
0.013 Tw 1.6875 -1.25 Td
[(exposures \(letter\). Am J Emer)20 (g Med 2005;23:585)-25 (-)-75 (6.)]TJ
-0.01601 Tc 0.01601 Tw -1.6875 -1.375 Td
[(34.)-484 (Carstairs SD, W)40 (illiams SR. Overdose of aripiprazole, a new type of an-)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.25 Td
[(tipsychotic. J Emer)20 (g Med 2005;28:31)35 (1)50 (-)-25 (3. )]TJ
T*
[(doi: 10.1016/j.jemer)20 (gmed.2004.09.013)]TJ
-0.035 Tc 0.02 Tw -1.6875 -1.375 Td
[(3)-15 (5)-15 (.)-496 (G)1 (u)-1 (l)1 (isano M, Cal\223 PV)130 (, Cavanna AE, Eddy C, Rickards H, Rizzo R. Cardio)-1 (-)]TJ
-0.03999 Tc 0.015 Tw 1.6875 -1.25 Td
[(vascular safety of aripiprazole and pimozide in young patients with T)70 (ourette)]TJ
0.013 Tw T*
[(syndrome. Neurol Sci 201)35 (1;32:1213)-25 (-7. doi: 10.1007/s10072-)-100 (01)35 (1)50 (-)-99 (0678)-25 (-1)]TJ
-0.01401 Tc 0.01401 Tw -1.6875 -1.375 Td
[(36.)-486 (Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment)]TJ
-0.02499 Tc 0.019 Tw 1.6875 -1.25 Td
[(of schizophrenia: safety and tolerability in short-ter)-25 (m, placebo-controlled)]TJ
0.013 Tw T*
[(trials. Schizophr Res 2003;61:123)-25 (-)-25 (36.)]TJ
-0.011 Tc 0.00999 Tw -1.6875 -1.375 Td
[(3)-1 (7)-1 (.)-491 (B)1 (e)-1 (r)-25 (man RM, Marcus RN, Swanink R, et al. The ef)20 (ficacy and safety of)]TJ
-0.019 Tc 0.019 Tw 1.6875 -1.25 Td
(aripiprazole as adjunctive therapy in major depressive disorder: a multi\-)Tj
-0.013 Tc 0.013 Tw T*
[(c)1 (e)1 (n)1 (t)1 (e)1 (r)41 (, randomized, double-blind, placebo-controlled study)65 (. J Clin Psy-)]TJ
-0.02499 Tc T*
[(chiatry 2007;68:843)-25 (-53.)]TJ
-0.01401 Tc 0.01401 Tw -1.6875 -1.375 Td
[(38.)-486 (T)35 (ran-Johnson TK, Sack DA, Marcus RN, Auby P)110 (, McQuade RD, Oren)]TJ
-0.005 Tc 0.005 Tw 1.6875 -1.25 Td
[(DA. Ef)20 (ficacy and safety of intramuscular aripiprazole in patients with)]TJ
-0.008 Tc 0.008 Tw T*
(acute agitation: a randomized, double-blind, placebo-controlled trial. J\)Tj
-0.02499 Tc 0.013 Tw T*
[(Clin Psychiatry 2007;68:1)35 (1)35 (1)50 (-9. )]TJ
-0.035 Tc -1.6875 -1.375 Td
[(3)-10 (9)-10 (.)-485 (Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the prob\-)]TJ
1.6875 -1.25 Td
[(ability of adverse drug reactions. Clin Phar)-25 (macol Ther 1981;30:239)-25 (-)-125 (45.)]TJ
0 Tc 0.05099 Tw -1.6875 -1.375 Td
[(40.)-500 (Pandharipande P)110 (, Cotton BA, Shintani A, et al. Motoric subtypes of)]TJ
-0.008 Tc 0.007 Tw 1.6875 -1.25 Td
[(delirium in mechanically ventilated sur)20 (gical and trauma intensive care)]TJ
-0.02499 Tc 0.013 Tw T*
[(unit patients. Intensive Care Med 2007;33:1726)-25 (-)-25 (31.)]TJ
-0.02 Tc 0.02 Tw -1.6875 -1.375 Td
[(41.)-480 (Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.25 Td
(Clin Psychiatry 2005;7:268)Tj
0 Tw 10.39912 0 Td
(-74.)Tj
-0.019 Tc 0.019 Tw -12.08662 -1.375 Td
[(42.)-481 (Product infor)-25 (mation. Abilify \(aripiprazole\). Princeton, NJ: Bristol-Mey-)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.25 Td
(ers Squibb, February 2012.)Tj
-0.013 Tc 0 Tw -1.6875 -1.375 Td
(43.)Tj
-0.01401 Tc 0.013 Tw 1.6961 0 Td
(Muzyk AJ, Rivelli SK, Gagliardi JP)Tj
-0.0135 Tc 13.91348 0 Td
(,)Tj
-0.01401 Tc 0.48641 0 Td
(Revollo JY)Tj
-0.0135 Tc 4.27607 0 Td
(,)Tj
-0.01401 Tc 0.48639 0 Td
[(Jiang W)90 (. A retrospec-)]TJ
0 Tc 0.022 Tw -19.17094 -1.25001 Td
[(tive study exploring the ef)20 (fects of intramuscular aripiprazole on QT)70 (c)]TJ
-0.024 Tc 0.02299 Tw T*
[(change in agitated medically ill patients \(letter\). J Clin Psychophar)-25 (macol)]TJ
-0.02499 Tc 0 Tw T*
[(201)35 (1;31:532-)-125 (4.)]TJ
0.02 Tw -1.6875 -1.375 Td
[(44.)-475 (Endo T)75 (, Katoh T)75 (, Kiuchi K, Katsuta Y)130 (, Shimizu S, T)70 (akano T)75 (. Famotidine)]TJ
0.013 Tw 1.6875 -1.25 Td
[(and acquired long QT syndrome. Am J Med 2000;108:438)-25 (-9.)]TJ
0.00999 Tw -1.6875 -1.375 Td
[(45.)-475 (Lee KW)90 (, Kayser SR, Hongo RH, T)70 (seng ZH, Scheinman. Famotidine and)]TJ
0.013 Tw 1.6875 -1.25 Td
(long QT syndrome. Am J Cardiol 2004;93:1325)Tj
0 Tw 18.2724 0 Td
(-7. )Tj
0.011 Tw -19.9599 -1.375 Td
[(46.)-475 (Nakamura Y)130 (, T)70 (akahara A, Sugiyama A. Famotidine neither af)20 (fects action)]TJ
-0.019 Tc 0.019 Tw 1.6875 -1.25 Td
[(potential parameters nor inhibits ether)20 (-a-go-go-related gene \(hERG\) K+)]TJ
-0.02499 Tc 0.013 Tw T*
[(current. J T)72.4 (oxicol Sci 2009;34:563)]TJ
0 Tw 13.06836 0 Td
(-7.)Tj
ET
0 0 0 0 k
50.5 14 378.5 14.524 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.02299 Tc 10 0 0 10 50.5 21.6856 Tm
[(e1)57 (1)]TJ
ET
BT
/T1_2 1 Tf
0 Tc 5 0 0 5 73.1366 23.1856 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 86.3177 21.6856 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 5 0 0 5 219.4427 23.1856 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 232.6237 21.6856 Tm
[(2013 February)55 (, V)110 (olume 47)]TJ
ET
0 0 0 0 k
463 17.694 80.5 10.806 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
0 Tw 10 0 0 10 488.4582 21.6616 Tm
(theannals.com)Tj
ET
0 0 0 0 k
50.5 740.1929 234 10 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.0251 Tc 8 0 0 8 50.5 744.7228 Tm
(S)Tj
-0.02499 Tc 0.013 Tw 0.76835 0 Td
(Nelson, JG Leung)Tj
ET
BT
0 g
/GS2 gs
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 284.35733 11 Tm
( at UNIV CALGARY LIBRARY on May 25, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
16 0 obj
<</BaseFont/GUCSMB+Times-Roman/Encoding 13 0 R/FirstChar 32/FontDescriptor 15 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 833 0 0 333 333 0 564 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 0 564 0 444 0 722 667 667 722 611 556 722 722 333 389 722 611 889 722 722 556 722 667 556 611 722 722 944 0 722 611 0 0 0 0 0 0 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 564 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 444 444 0 333]>>
endobj
20 0 obj
<</BaseFont/SBQZQS+Times-Bold/Encoding 17 0 R/FirstChar 44/FontDescriptor 19 0 R/LastChar 101/Subtype/Type1/Type/Font/Widths[250 332 0 0 499 499 499 499 499 499 499 499 499 499 0 0 0 0 0 0 0 721 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 443]>>
endobj
32 0 obj
<</BaseFont/AYNBDC+ZapfDingbatsITC/Encoding 29 0 R/FirstChar 110/FontDescriptor 31 0 R/LastChar 110/Subtype/Type1/Type/Font/Widths[761]>>
endobj
28 0 obj
<</BaseFont/NMVPJF+Times-Italic/Encoding 25 0 R/FirstChar 32/FontDescriptor 27 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 0 250 0 500 500 500 500 500 0 0 500 0 0 0 0 0 0 0 0 0 611 0 0 0 0 611 0 0 0 0 0 0 0 0 0 611 0 0 0 556 0 611 0 0 0 0 0 0 0 0 0 0 500 500 444 0 444 278 0 500 0 0 0 278 722 500 500 500 0 389 389 278 500 0 0 0 444]>>
endobj
56 0 obj
<</BaseFont/RSQKYE+Times-BoldItalic/Encoding 53 0 R/FirstChar 32/FontDescriptor 55 0 R/LastChar 122/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 722 0 0 722 0 0 500 0 611 0 722 0 611 0 0 556 611 0 0 0 0 0 0 0 0 0 0 0 0 500 0 0 500 444 333 500 0 278 0 0 278 778 556 500 500 0 389 389 278 556 0 667 0 0 389]>>
endobj
69 0 obj
<</BaseFont/Helvetica/Encoding/WinAnsiEncoding/Subtype/Type1/Type/Font>>
endobj
53 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma/hyphen 65/A 68/D 71/G 74/J 76/L 78/N 80/P 83/S/T 97/a 100/d/e/f/g 105/i 108/l/m/n/o/p 114/r/s/t/u 119/w 122/z]/Type/Encoding>>
endobj
55 0 obj
<</Ascent 700/CapHeight 669/Descent -204/Flags 262242/FontBBox[-200 -216 992 921]/FontFile3 54 0 R/FontName/RSQKYE+Times-BoldItalic/ItalicAngle -11/StemH 0/StemV 79/Type/FontDescriptor/XHeight 685>>
endobj
54 0 obj
<</Length 3414/Length1 3414/Subtype/Type1C>>stream
  RSQKYE+Times-BoldItalic   C¯ ¯¯¯¯Ä˚\˚l˙t˙-
 ãã
 ãã  	    DØ  2 }éì002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku Bold ItalicTurku    4  / F M T P O  + ( - V H 5 S B E 1 J U " G N X  % Q [    |  ÌPôW»ÌD¬£Y´˝u zÁ4ë		Œ
D
`
ŒOÆ-y≠˘Æáw˜˜˜¯˜≈¯@Gø}ü∑Õ±≥À‹µY˚ï¶á¯≥˜\nyÅÑu¯]l®ãA˚26!˚?˜â_ã˚!FVVC!^·Òàmåh˚s©ßóííûØ∑hÊ˜‰€˜ﬁi»˚Ì¸$”ëvö§¯ˇ§p˘ô˘~˘1˚er»Öû}cxÑjÄb<˚≤˚l¯d˚Vr¡ÜñÑû`˚¸.e˚ÑÇS}r˜e§Rérù±ûí™ó∏Ì˜˜˜ñ¸π¶˜#¯é±˜êï≈ï˚b~À˜´˜l¨ê˜#˚#˜˜>ÁÙ˜(˜j˜´æ‡∫ùîu(AM8v˜<CLegocÏ^uß¡úåîê¢Âî˜:Œ˜Ω`ØO˚'˚"˚<˚13 L‚Ÿ¬≥Ìƒ¸óvç˜≥˜µ˘P3ymá1Çq¢≥èjw}\Ñq'˚ˇ}WÑjãzb§sµ‹º÷«≤uöiUqqyãÇÖíïóí¨ö¿˚ôìvå®¯1´äwπÎ¥Í\˜ﬂ¯ao{ÉÖÜ}|nv°ã^:VZ?TônŒ=≥[õmrlrsjYj∫·~qé¸u˚:•ôììëô|°§xã∑‰»¬Ÿı˚‹ã“ßü¢´∏©c<ò\¶à˚*}©¯5®à˜˜`˜˜Ø¯b˚'˚˚3˚;5œKÁ˜%˜˜0˜9ËL….Én©äövaBS˚¨+iy°∑÷ø˜≠ˆÜ-óv©v¯bw˜wp˜Ö¯aS~YÑ.Öp†´åoqj äÜãÉlP˚h˜˜Ë‚Ω•òñÇ~i4˚[ã:b£u∏ƒº¥ÂæuòeP}{zäÉÑíï§„˜iã÷Ωp¢X6N/*Jâç¸$≈‡\˚I˜πŸÊﬁ√h≥Ybnl`M—éãbeZ[Fl˚*(Ø˘W§]˜È˜¯N¯—ô¿ôó¿ë§˚ºr¶àπähÇáwÉn˚¸Ee˚%|khãxÅëó†¢êã©≠o¶fhpldQÃ`·˜À∆˜Æ”y±˜±§˜‘Ø†˘?˘:˘BntÄ~Ñzl`©4˚5kG>*6R˚˚˚5˜˚˜G“˜ †§Ωßôª˜Hû“êë¡ë§˚≤râòñäë≠áïÇrp_˚?}{y{f_(N—˜˜/Ë˜∫˜SÂ∏P˚é®Üdã´¯¯§u¯˜¯…˜\˚I+U˚_vï†íçôéñ˜¯rô¡°õÀå§˚œr…ÜóÖpÄÜoÖw˚¸V~Zy{ZÑr¯º∆˜W-óv¯_w´wö¯p–¯{¯V˚
a˚&wUgGfFZXnã}ãÉîãõãñê°ï¨È˜…EÅI|Bâpªáìáu}ÜsÄf_˚+ÇkÖjãxV£s¿¬≥¶ÿ√ìñèë™∂çâ{\Öopc°w∑ƒ≈∫‹∑vòfUxx|ãÅáëò–ôìØöæ˚*˚_≠˜Kv˜4´˜ã™W‚ã˜˜˜ @˜	ˆ˜ÑùÿoÇù•~öwt`_qEC^©ª∑»≥õı˜!¯K®útcWi˚En|ü±æ¨˜–˙˚C¸>+uipSN◊`˜ ˜&Î«Ê«g¨˚™VöiïyôãõõúùòöôÉã†ı˜Í⁄ÌúäíáûŒ√˚•ikìa˚$9*V¶d¿v9]}}emùw¥|dã§¯ıÆi≠Ω¯Î˘˘1¸∫e˚?§ÑπÏ…¥˜ë˚'¸Ø|UrzIãr˜ﬂ§CéÄë™òê®ë†˜¯éÓÜ™hì˚¶â˚ô†v˜◊˜ v¯-˜w¯cQ|âã˚ ~p∂äñÜw}V~]>˚°˜Ω˜2©Î ˆ•ãúìeãÆÆ£©∑¥u§h\`X˚JÜé˚*ívç—˜ˇµv˜p˜û¯9¢äôxnIH˚å1rx¢™Ã‹˜çﬁÜ˜PØ˚ÖySâ∑Ös£b˚˚)˚R˚3=µ[Œ«∑≠Á√çåÄbâÉã}dßp≥∏Ω∂ﬁ¡vöfWxx|ãÉÜëïßë®ßÁ˚*”D“˜˝µv˜p˜¢¯9¢öwkbD˚†/rz£ÆÕ€˜Ä‚˜ä˜´FyWÜ4Öp†ßòÇwÑázÖue˚t£wîpã˚
˚/˚S˚1B∏U«ÃπØÊ¿çÇcäÇ{pd°u±ººµﬂΩuõmZwu{äÖäÜëì¢∫˜:î¨dã§˜πÆ˜±™s£¯e˜&Ë˜‡¯Â±ïìí¨æ™iRWyMrhmud|SÄÑãçxÇká≤úä§˜7˜ Ÿ˜
ÚDø˚"˚≤¯sœÇëào~áuÖt˚¸V}YUÅr˜∫§Qè~ì©óé¢ë°¸óv¯√˜˜˜˜V˘@fmmff©m∞∞©©∞∞m©f®˚r/zÖä#ÅqπäóÖrÜâÑá{S˚lÄbávã|e¶q¥«√∏ÂøuôjWqoxãÉÑíìîäãîÆã»˜z™˜¸óv¯4∂Ä˜∑˜ã¯ÁhZ>^f2dhæL˚pÇmxFãn`•r∏≈ª≥Î∆uôgStsyãÉÑíìöìØú»»˜oﬁ∂Cúã§˜L≤¯Hw¯˜ ¯/˘@s¸¸‡m\x{hÉr˜Y§Zézì§ñëùîõ«Ú˜jãö7ã_d|ÄKÖr˜√§KèÑì~’˚\¯±˚â˚M˚—˚`˜˚™¯Ÿµ˜˜Çv˜˜	˚˜™˜Ä¯Vù“§Ï©æ≠ãóëáÉÄ{Åãw≤o†u¶©††´ªd´Q˚ @8˚:_BÉaÙ‘|NÑmáwM˚≠,v~-SÄÉêëîõìã§¥ßwûmoutn\≥k≈˜=Ω˜f¯&‹‰îµ˜óv©v¯‘äw¯⁄˜h˜}¯aO~~â˚q∑äïÜwÑåÑk˚ãÉkM˚q˜˜˜Ê˜≠ññíÇ|Çâ~Ü|ãG˚oi˚˜∞˜µ˜·˜πãôïÅ~b3˚Oã8Ë_¢vπ«¥≠Ï√uóeQ|z|ãÇÑíì∞„˜LãÁ∫m®YXL`˚?éú∏ê°®¯¥q§b-D˚H]àçúìv¯ow†w˜¬Ô˜÷ÿ˜È~÷€˜X˜e˜±r¶hmqolc¥wãineQ:/¯l˜·o˚-˚•âÿà˜Ç◊v—WÇXÇWÅq∞äëàìv£Mì˚FâDâ6¶ƒ·¥…≠–ØÃå¢˚Æ˚—†v˜:˜ç˜†ç˜:˜â¢˜˚â”ã≠¯Ò©r§¯¨˜'Á˘1rœÉëÑoÄâÖ{P˚¸?}X{|YÑr˜≤˜ï˜N˜9˜x˜D˚Ô˚TIGßíõïÆ˜¿N˚˚f˚WCBWBf5ayñ£ååòããó∑˚*˚`•˜:Æ¯”˜‘˜˜k¯c*{£é˚|pπäìáwÅÑnÉj˚¸>~X}Ä_äq˜å•Xå}í•ß•Ÿï∫{´õÜ°˜˜"˜J˜<Ÿb∫IZ\p;RâèÔ™£ôxlAD˚à*uzõ†¨¥˜ô¥€ß∫∏≤˚ô<˜"˜∂Ï˜áÒ¯¯V˚À`˚/ßàõ∏õõ©ã˜$˚∂˚ˆ§uöïúùüã¡«7ãÊ∆∫¥æßt°lqutqmüÜã}ÇÇÖ~zÉí£~aŸzùQ•˜≠˜Âxû¯Vò˜bõöã˜úñ¸vé§
⁄å
_˜é˘
endstream
endobj
25 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 46/period 48/zero/one/two/three/four 55/seven 65/A 70/F 80/P 84/T 86/V 97/a/b/c 101/e/f 104/h 108/l/m/n/o/p 114/r/s/t/u 121/y]/Type/Encoding>>
endobj
27 0 obj
<</Ascent 684/CapHeight 654/Descent -205/Flags 98/FontBBox[-169 -217 1009 884]/FontFile3 26 0 R/FontName/NMVPJF+Times-Italic/ItalicAngle -11/StemH 0/StemV 23/Type/FontDescriptor/XHeight 677>>
endobj
26 0 obj
<</Length 3398/Length1 3398/Subtype/Type1C>>stream
  NMVPJF+Times-Italic   C¯ ¯¯¯¯Ä˚=˚m˙Ö˙
 ãã
 ãã      ¸  =¨  % }âé002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku ItalicTurku    5 I F  " O B M T P G 1 S N D U Q Z     ' C V  7       Y ÏLO≥Eø|¡>≥ﬁ+ü ≠ZÆ		ò	˝
ç
ªVÜ¶-†v¯ˇÆ∆¯—˘˘"¸ßa˚.ùá°∫ú§•ü§¨¶ë˜˚#¸•}YszFÑ{˜∂õ9ëÇè´ïë•í•˜ ¯á¡÷®rKÅäÇâxúä˚*óv©v¯Ovû¯]¯pÙó_QvwzãÉÑíïñëôçìƒ˜eïÆë©ãò≤pßfKFM˚#-âç˜
¯KÖêL}wÜBÉz§åúå§âãtuj|P˚¸ã÷±˜)õµ≤∆¡‹Õ∆ÆãõãóÄã}ãÜåãÉnW˚S}WÇapú{ßæ∑Æ⁄ª˚bÅ∏¯¢™·˜yÃ¯/¯
∏o¢T˚˚2˚9˚&3æV‡Œ’≤œ…óCQk{`ãSe∞¡ôéüí•®è˜,†Ú◊ã‚Jí7+G˚vù∑∞Êœ‘¿é†åö{t¸$d†v˜vØ¯+vX¯˚¯»õSéÉï”,¯Ãq˚µ¸âA˚}{bÉ{˜Oõ\ê~í¢òì•ó¢≈˜˜pü˚åÅåÇãÅgx~Pä{æ˜ö˚V˜(˜òç˚*óv©v¯Nvô¯`¯nÛ|òUFÅÅyãÇÖíîíê†ï±∑˜4ó∑î¥ãö∞q§e,4˚&H^âçÀ˜eáç˚tëå[Ç{æâòÜx~ÇnÖvãÉl@˚ß÷¥˜$¢√º— „±¨ØãòãïãzãÄÖlÅf`˚7{PäÉ|lõ{´π©§„À˚*Äº[ª¯°úﬁ¯pÔñ~~YSyãÑÜêìïê¶ñµÿ˜∆ÖéLÑÄ[äåÄÆoûdã˚˚1˚J˚-=ÆbŒ—≤©˜„çà{LÜqãwoò®±¨•ﬂÕ˚˜î3,˚z!drß∑ÂÈ˜q˜Æ¢qd¸ïv¥˜Ç˜´˘;ÜêQ{à9{§ç∑ärÑèñv>"¸v;à}ãziõy™¡ß¢Ò—îUCwxuãÅÜëïíéöì©˚ôìv¢v¯A£åv˜ ‘πÿ|¯¯O}}ÇÑá~|nqúãcC[aJ-˜?ã@[nkaRl≥Ïz|¸w˚4öõíëêñ|≠™xã±ﬂ…¬÷Í˚Ÿã‘¨¢ü≠Ω´g=ï|õ˚*ïv¯Yv¶ﬂ˜¶ﬁ¯h˜πËU√2˚(˚*˚0˚-/¬WÎ˜ ˜*˜<˜8´)B˚m˚[k∞¬Ó›˜p˜∂ßfP¸˚Mv¯Ô´˜x°ØÍ¯:¯˙±g¶Xaexdjibu\j#0ÉkÂ3¸9t˚lX_ãÑëïîîêãô†zösw}zsi¨q∑Â–Ï˜Mµ‘˜’˜ ë´ ˜0¶±”¬ôïÜÑäÜÅÄã|sö{°¢ùù°d†v˜≈∞˜Æ©¯âÚ¯¯äÓB¿˚˚åz´Ü±è`}áv`˚
¸={RÑÖPÄ{˜âõSíìßöéóî≠¿˜U∂Ö§â±ã˜,Û€˜	$ë˚OW˚xtçè{—˜ãë†óì®ãÊ¥g;˚ô†v˜ËÒåv∏¯¯0¯™xünX@7(^Çwäçº˜[àéWÅWÇWÇ{éûìåì†òÅy~ÖiÅh:˚π◊∂˜ ö¥Æ–∞’µ¿†ã†fã∂®úû´”óv©v¯ø\∫ó˘Fx˘RÙ}óZOxyzäÉÜêïîåêí£ƒ˜gî≠ë©ãòØsßk24˚Haâç¶„ï±ãúØt£iO?D˚8àéƒ˜[àé$vååPÄ{¿äñázÉçë{M8˚ ÷™üﬂ…„x—º¬ª®òìÇ|Éåç|Tãâ;˚∫◊≤˜,†¬ªœ∫œ¡ª¶ãóãîÇã}ãÜåéÄ^Z˚Z}Qáz~¯oö{¶π∫∞ÿ¿˚bÄØ¯5w©‡¯<˜¸Ωa´H˚%˚ ˚'˚.)øUÎ‘…Æ‘¿{îcZSk[ãSh∏“˜$Ï˜Ò£öÉ{|Çãruõ|£¶ûû•¸ñv¯+¨Ø˜ò˜º¯B;ßÚåçãçãçêàèÖÖääÄÇ\Sbib{mÄáàãÅãÇãîãÇ÷B˚ßt5åéãÇuä†y¶§£ñü¢ùõòú≥ƒ~ërlpj{}ãÅÖëñêåçèõﬂ˜“ﬂ˚*˚Mv˜Wû¯∂¯Â¯i˜…ﬂaºBL[l=TâéßÓáí˚0uéz©é≠àãpÑÜsÇj˚¸N~YÖÖ[Ü|˜bö\yî°©®ìÆ}¶òà®˜!˜0˜=˜+1ì˚(˚ ˚5'ltö°πª˜(ùπÃ§ƒºø≥°mW˚b˚Lv˘v˜‡Èc≥–¯>¯≤u£h‡v{|w–Z¡óãdP,˚/p]w˜Ö¨N˜qyãvE}ÅVzéüìåî¡§Y˚lºöGïV~{Ñ|tmxqplwwÄÖÇãwã}®pãtãz{ãuãpüy™ã∞ãº≤–‡˜	˜#˜˜Éã⁄˚*ã÷¯•‘¯‡¯W¯éÌF‘-*?Q%güÑ≤Õµß…ã“¿WDP`C%˚˚e˚tz˜˜Ω˜zírXv~Uã˚Rê˜U˜U˜
˜
©∫ãœ˚*Ñß˘ß´⁄˜»Ÿ¯Ö¯H˜*OÊ(˚.˚,˚|˚~˚Œ0Í˜1˜&˜j˜y=‚˚*T˚]J5_jjvhUjΩ‹˜Ω˜U¡Ó∆¨∑≠∑ø™\<˚*†vº˜¸¯-˘0ëâçáÑ2v{+{†çØãã£åòÄxÉãÖÖw˚¸ÇÄeÇá0}˜´ôtåKá∞íâÉ†÷˜#¯öèöçîãè˚*Ö±¯Ôµ˜Ÿ€p‚–¯e¯Ω—O¡<FKcLlöÜ¥º®ú∑ãæØfU8,I˚$zå{°‡Ù≈N˚3QCDzrñüm•eÑéwpz|rf¥v”˜1˜˜˜#ÿr¥E≠é–˜ª¨´“d†v˜€Æ˜ó¨ì˘˘˘"¸Ü{œÖïÜn}ÜpÖt˚¸O{RÉÑRÄ{˜êõQèyñ®ñåèì©…˜s≈ä¡äπéãYxâ|ÖsúÖ◊˜xëZ,ìè˚BàÃ˜}ë¢ïéÕã˜,™~M}ãÇâxüâ˚*Å°¯º¯‡¯n˜‘‘[ºD2V:J^äç¯ÜêUÇêã#|{†â∏ënyfá{˚¸äàr’n…˜)˜:˜B˜06~#˚˚S˚h|ó¶ÏÎ˜â˜µßiW˚*Ä¿mv¯Nv™v˜‡˜∏¯o˜ }î[Nyy|ãÑÖëïóçåòºãê†Ÿ˜ºAa˚rT`HP/XUnãqãç•çìÊ¯ ∏àéQ}zà@Ä}†â≤ílÉãäÇgY˚W\ÜpãzgùxØ–ææ˜O˜çh˚Éhw¯lúy©œØ–ªÆ¸$á˜˜¨≥sßinvxpzíù{ö}êÉrurVgïx‡º∂¡ã∆dév˘4v◊¯¯˘D˘õ˚N{øÑñÖuy|hfK˚^˚ÛáI¯Jäëãëãê´öî…íõ˚Ö{¿ÑëÉô9Á¸√û¯¯˝õ¶ôï•ç˚*†v˜EÕKÀå¯q∞¯r˘:c¸5¸CwG˜ôZ˚G⁄∫˜EÓöÕ,ô˜◊,˚◊˚iç˜≈˜’˚*òv¯Ô‘÷¯a¯¨˘&Öï¸
:˚òÇº≈•ô∆ã˜rçà¸¸Ï“¸$Ä˜¶˜˜∑™r§mlrrlm§r™©§§©xû¯Aô˜g¢íã˜°ç¸sé°
¢
_˜é˘
endstream
endobj
29 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[110/a73]/Type/Encoding>>
endobj
31 0 obj
<</Ascent 1667/CapHeight 1667/Descent -293/Flags 4/FontBBox[0 -143 976 814]/FontFile3 30 0 R/FontName/AYNBDC+ZapfDingbatsITC/ItalicAngle 0/StemH 0/StemV 0/Type/FontDescriptor/XHeight 0>>
endobj
30 0 obj
<</Length 178/Length1 178/Subtype/Type1C>>stream
  AYNBDC+ZapfDingbatsITC   6ã˚πœÉ
 à?ãã
 à?ãã   h   e   kë   ¨ a73    á %<¯
˙0˚π…˝Ã˘7˘Ã˝YV¯Á˙¸Á‰˙!—ç˙s˙sçç¯Õ˘
endstream
endobj
17 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[44/comma/hyphen 48/zero/one/two/three/four/five/six/seven/eight/nine 65/A 101/e]/Type/Encoding>>
endobj
19 0 obj
<</Ascent 912/CapHeight 676/Descent -203/Flags 262178/FontBBox[-168 -218 998 934]/FontFile3 18 0 R/FontName/SBQZQS+Times-Bold/ItalicAngle 0/StemH 0/StemV 25/Type/FontDescriptor/XHeight 921>>
endobj
18 0 obj
<</Length 1549/Length1 1549/Subtype/Type1C>>stream
  SBQZQS+Times-Bold   @¯ ¯¯¯¯˚<˚n˙z˙:
 ãã
 ãã   ˘   ı  ∞  Ë }áå002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku BoldTurku           "     F     < ì ≠béz‡ m›E∞˚+ã§˘+w˜O˜&¯N§1çxõ◊¯Õz˚è˚q†ƒôèô§óu\¸:wz(är˚+ã˜¯M˜˜Ω˜¯q˜hrEo|Ç(˚*˜3˜.ﬁ€´«ã÷˜@◊˚*DI˚Y¶ƒ•∂´ø–ºV@YwSaN^K]U˚˚s¯3˚“†v˜@˜∑˜Ü˜≤˜@˜˚Ü˚˚+†v˜#˜¯Ew˜ù˜&˚$˜$Ë¯m˜#˜M¯E;dYk_xr˚˚4êë#˚2˚˜ä˚#˜&˜#Ë˚$˜˚c˜a˜ªËç˚+É«O˜(˜S˜‹˜¯	ÿ∏¯i˘8˚’+˚Ì˜
Å∫ÉªuŒm¥VTU^\X¯DZ„ãBgqrhV»hÂ˜4˜	˜‹fÕH≥V´eì˚î°‹˜©˚+†v¯Ø˜ú¯^¯o˘8¸3`˚r§Àú£†√˜b˚Z¸ØÍ˚+~™˘ßß˜˚˜˜9˜˚˜
ÿ¯j˜M„b«˚“‘‚£ºΩÃ„A√˚
˚ 6H˚A≥UÔPË"l]X5&·H˜˜Á⁄˜‘˚˜ÙaÇgjeR®Cƒ“∂±±∑¬≠]?ËÖ¸+Gi_XOe¡‡≈ï™≥∆˜C£kD“ã§˜@≤¯Zwî˘9˘B£]èÅóW˜˚s¯¢n˚p¸∏e.ÇYr˜_§Oètó§öò±´Ÿ˜sßQûRt~ÉÅ|àÄàéãYÜrû˜Ä˚VË˜á˚+~•˜Ñπ˜˝¶•¯R¯l¯&˜>.˜˚˚1*˚˚’9ˆ∞£êô®]˚0DD˚(kq˜ù§˜C˜8˜v˚1¶häoÉSÜsÖxMt≈˜5˜ó®ª°ùÅxïõoñ62¸$öv£v≤˜L‡˜sµÕ`∫O[jj[[©k∑‡ííéãìóìÇ}fkd>Sñt…∞¢û¶©¨±†æª˚+~ß˘ß£¯V¯n˜ﬂ˜b,˜*˚˚,˚+˚a˚ZÎ˚&˜˜Î˜&˜Z˚2˚ ˚'wN\\w»˜'˜y˜&ü»∫∫üN˚&˚+}˜(˚(Ω¯œ€˜≠˜&@˜®¯f˜ã‹b«:Ø∞À±û©«ﬁMø(&@Y$U†Æ«∞§¿ã«≤bMIig,mxË˜ `«P+EdZT®DqÌã7iprlS«gÈ˜9˜˜˜&˚c}”˜O∞˜4©§˜$˚$˜˜˜Ù¯<˜tôaXo{_ãBc ˜Ü˜è˜*ÑJÿ˚	˚6'˚ ˚&›'˜ﬁ¡≠Ê«Ï˚˜?˚˜†ªΩ•ü{líëuãÉé8˚+~¶˜˛π˜Ñ•ß¯R¯n˜p˜Aﬁ˚ kxá}e≥˜*—–˜/≤•˚®j˚8˚/˚w˚BÊ˚˜"˜ÊÓ˜˚-K˚nZuyñ°Ä|¶Ç⁄Âµç®ë∫íå†ìùÃ¢Q˚6xû¯aó˜_õ˜pî˜üì¸ué§
§å
_˜é˘
endstream
endobj
13 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 37/percent 40/parenleft/parenright 43/plus/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon 61/equal 63/question 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W 89/Y/Z 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 147/igrave 177/plusminus 210/quotedblleft/quotedblright 213/quoteright]/Type/Encoding>>
endobj
15 0 obj
<</Ascent 684/CapHeight 662/Descent -215/Flags 34/FontBBox[-168 -218 1000 899]/FontFile3 14 0 R/FontName/GUCSMB+Times-Roman/ItalicAngle 0/StemH 0/StemV 84/Type/FontDescriptor/XHeight 677>>
endobj
14 0 obj
<</Length 8321/Length1 8321/Subtype/Type1C>>stream
  GUCSMB+Times-Roman   @¯ ¯¯¯¯˚<˚n˙|˙
 ãã
 ãã   ˚   ˜  ö¨   ` }àç002.000Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku RomanTurku  N  B M P Q F S J E   G T U  H O Z D I C N W V 	 * $ 6 
  4 ( " ) X [ R 0 Y & 5 L 1  %  2       '   .  + / 3 - K  ú    8 #  : , ; 7 i w   ÷  P   ê »õ˘f¡9ux’d∞«ë~À9õMÆ		V	ç	ˆ
\
ù
Ω7ÆzQæûgÏb–4O–?¢œ4ÖÛ,≤ñﬁ>¥˙e‘—ÙPÔé«5π¯TΩ#è˜"˚bñvåƒ¯§∞„˜6›x¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω∏Tëùx∑™ßõ≠ß˚0ﬂsàÄÉx{yb{sfo≠π»∫µ˜±¸†vÏﬂ˜îõMå~ó√¯ÁáéHwvÖEy{åôíãó∞ìÄY¸pV{}Ná{˚*Ç¶¯4ß®‰˜ö‰¯i˜~˜0È˚˚0+˚˚Á'˜˜ÍÛ˜2h˚^FA8O˜˜*ÁºÃ–ﬂ«*˚˚*˚Vv˜a´¯«åw’ﬂ˜v‡Ï¯i˜à˜F‰*R_sVaâç‘‹ÖéTvää4m{åóéãó´ëÅ[¸gUÑÑMÑ{˜ÖõAå}ó…˜0m´©≤˜Ê˜˜$6f˚YAArmóûs}óÇóï˜äÏØìª™∫’º>˚˚bÅ–˜o´˜Ø§–F“˜cÒÙ¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÏ˚˜-˚cŸöÆØ«∆•m7ó˚—†v¯`w†w÷ﬂ–˜‚¯+¨wühblsH]â‰∞ÜéJqwÑMu{éöìåï§ï{_˚éYÇÉNÅ{˜ÉõKvùƒ˜súò§ûûôòôìîíìáÉîx†ìáõ°õû•¸†v¯^w˜$◊8ﬂ˜E˘ßt¢opttop°tßß¢¢¶÷˝õËKèÅñ”˜˜ÜèWwZyVy|é©åãì¶î{_˚{CÅGà{˚*Åø¯ß¶·˜wﬂ¯µõÉÇäãáfÇó∏¯ÀÜéUx|á=v{åòëãêØìÇa˚0¨crïb˚.˚˚˚◊2˜¿µ†∂™çNêàŸßoÅÎ≠˚+»m^l_9Sﬁ˜˜æ◊‘¬ª\U¸$õv£v√˜ †˜Xñøh≤\jrskl¢wØ`ôêéãîïêáÅäâiogVgïxŒ≠∏»ƒ¸$˚—†v¯7´˜_®Úﬂ7ﬁ¯˘´\ßU˚QA˚2ä:k‹˚œBÅÄBá{˜òõ:çñ÷˜œ˜´Ë˚˜∆ùß≤†îÖoük°îÑú¢ûû¢˚ôÇ°êv¯Zwí¢æ»˜:—ú˜˜ªt´M∞ Ànú|§ã©Ø≠®∂≈Æd6úõ¨á˜ÉÜáâÖÜÑåéÖúôcçs:QXDO™e·Z≈j≠xùqãn_koYEiØÚs{\˚/òîíêéîìïäàñúÅ¥§á•Ÿ ƒ”¸Åø¯´–ﬂ˜™Õ~ñvrzÅtãg|¶ ˜≥´&˜ñâéÖU<midpÑÜâàãÖãáåâéãø˚¬5©b…∏≤§æ¨˚—†v˜UÀ≤˜ä˜±˜UÀ˚äK˚*˚nƒ˜&÷@‘Ê§˜k≤êßß–nﬁ˜EŸ•®›¿¯i¯≤?u~çìwù]têm*AE-L§h–gCKyvtuö|≤{æ¿FZnfgTÿ`Ô˜˜ŸÊ ]¥@é˚êTçsïãùîòûôòóòôìîúêÜ®ÁœÕ‰®áû|∞P˚Snf_›¿MaÃÌ»¶Æªƒ∏B.Û˚ﬁR?b˚ﬁ¿3M©µ£ïú≤π¨Ñéõâ§àªâ¿âà°Äãi˚*†v¯)¬åw⁄‹:ﬂ˜Eﬂ‘¯xõ]}õº˜yË^ƒB[p|ID€¨ÑçYxà@tyéôëåì¶ì{[˚ãS}z\â{˜göYê{ò≠˜≠Ãª√õî¨ª£kJ˚eN}xZà{˚*˚m¯Àwô¯`¯n¯Iô˚}ØàóÑzÑéîqB<˚q˚˜êÇûãíãñúííΩëô˚a}®ÜóÑîw˜˚ä¶PÆJ|tpG{rt|z||wuùloxzpk™r¥“µº˜*ƒ˜/¯-ñ©ôò°é˚bÅ”¯®§◊¯0˜(}ì`HapQã1K›˜ƒ‘ÿ≤ñÇcóëwïkö|£ã¶ûù•¡E∫<˚+!˚!˚⁄/˜ﬂ∆∫˜¿˚*†v¯+¡”ﬂ˜Nﬂ¯zõXêÇó–˜[ˆa¿9R_rQ`â˜¬Öè\{òè kzåìëãè∞ìÇa¸kFÇUÜ{˜kõTç~úŒ˜Öπµ´ù±∫¶eF˚ZGÄ}Rá{˚*Å´¯Àœﬂ˜w‰¯h˜á˜?Ë$SWlXpâ˜¡Üéa{U{[~{åïíãèÆîÅc¸úm„i⁄˜Ú˜˜!2b˚	]L5[\££˜ê∂µ¨ƒ◊ø;˚˜†v¯-øåw·ﬂ˜Lﬂ˜Kﬁ‹˘ôõRåïª˜c˜d∆=SXpSU≈xk§SbvÇXFÜáÉÜÅÉ÷ºÉéZyåã1pyéõêåñ§ïx^˚íV}}Sâ{˜rõYyô∞˜Øéïïóï‹£®´ó™ª°iC˚mU~Sà{˜sõSå|ú»˜ê∏´™ú∫¡ûn9˚gSÑÉPÑ{˚*ív¯ewû¯\¯o¯Gõ˚{´äöÄv|Çoy]=˚[%˜îÜòáúãíúòî¨çõ˚W{üäïÜó§s˜˚ø£NéÇòeîãíãèíù∑˜˜‘¶Œíî©ç˚*Åƒ¯(w—ﬂ˜Fﬂ=ŸË¯rØôYäñ∫˜Ï˚2{ÀáïÇY˚ÅràÄÉÅuy^wlcjÆµ˜€˚%{ªàò~[˚è;∫Y◊Ø±õ¶¶Ë∑∂9çàŸßîéæô˚—˚1v˘Íwª‡˜ƒ˚6˚·Z˜˜l˜[∂Ò˜ÓÇõ˚@˚@˚ã˚L˚µ#Î%≤aßt≤t˚—ãû˘û˜Ò˜Ãü8é~ó÷¯O÷òóﬁéü˚∫wﬁàò@¸O@~8àwú}∑¯Ov˜M≤ß˜˘˜yú=AOp5ã˚+,˜˜K˜SÂ˜	˜(ˆ“N˚∞°Ç˜tvÉu|wåÅå{éxíbôYìaã˚Zã˚!˚#ã˚]ã˚f˜˚˜_ã˜ã˜ øæ◊”}∑¯˙ûÚÚ˜¸∂˘S˘ü˚{w÷âûr(˚¢=Å`slakTtJO\ùÆnnÆÇ∞€˜‘‘ññ⁄èü˚Æy⁄ÉïÅB˚À˚@›6˜:˜HŸ›˜P˜ôõ†Ÿè˚—˚1v˘Íw˜\‡˜±˜ä˜aÛ+Òdµo¢d¢{˜5º˚˚l˚[`%˚(î{˜@˜÷˜ã˜L¸$Ä˜—˜˜I∑™r§mlrrlm§r™©§§©-~Ø¯¯¥—·˜~Ô¯~˜<€\ƒ˚’Q≠"º‹¿µ≤∆Â–L˚ ¶§u˜hvsÖÇÅzÑ|éê}üOwëq"?D)9≠a˜C˜>¨hNGZ\C0M¿˜Wu©˚h††çñóùØ´jÁ˜
„ÿÛ”}≥˜…û˜Æ≥´˜¯Î˘W˜„û˚íxŸáïÅ@˚4iOq?˚3'˜
˜O˜KÏ˜˜%Ù–U˚µ£É˜fuuÑ{ÄsÖÄçéÄ°Ejë\˚[˚"˚&˚b˚|˜A!˜K˜˜¬ù˜\≈ôö√é”ãû˜[¥¯4wö˘G˘Vü^ç}òl”˚ç¯Ãw˚d¸O˚!}xYáw˜Zü\äuô™ïéïëõπ˜
˜ö¥*ïtîlãpzÉWwÜ˜ó˚{˜˜ß”ãû˜º∑˜±ûıÒ˜√Ò˘PüAè~ò”¯Q”òò’èü˚®w’áò~C˚W˚√˜W”òò’èü˚®w’áò~C¸QC~~Aáw˜®üAè~ò”˜b˜√˚bC~~Aáw”ív°v¯dw†˘4p˘I¯Gõ˚{™àòÅy~áu~l0˚r<˜kt…çÑãò£ôì∂èõ˚^{µäôv≠%/˚\k‚H˜CãÜõäìíüòî¨çõ˚G{¢äîÄüX˜˚Èkòëíëëî©ô˜˜ÉÂ˚∞^úãåíìååªû˜˜Óúµêíûê˚bã©¯©¶¯¯6˜yèv*|~/ã˚˜¢¯*ö˚Ôà˚ú’ïôö»˜˚ù¸*|¯˚*˚Vv˜a…¯ß£‡˜|ﬂ¯|˚kõ]çzö¥¯ÍÜêNgU™|ê_ã˚,˚˚&˚Õ4Ï¿¿§ªπçä˚NT|~AÑ{‰˜ÎkÑ~t~srÖs>W◊˜˜	¡Ÿ‹Õ™kF”}Ø¯˛Ø≠˜¯?˜˘C˜ﬁ˜_˚˜#˚S˚T˚˚#˚_˚]˜˚#˜T˜S˜˜#˜]˚å˚T:˚	˚˚:˜	˜T˜R›˜˜˜ﬁ˚˚R˚*†v¯Wwú¯b¯sõhçyòn∑˚˜Xﬂ˜û¶ßõ≠åö˚3}¨áíá}~uU?~üèÖs≥x™Ñöãìãõïë´çô˚b}µäêá∞SÍ˚%˚˚9pd}Ålä{˜%õnÄêóìêóô°€˜‹˚õsãäãÄ{ÄÑrá{dã±eû˜»µb¥˜ì≤xûÓ˜ú¢¨¢´Ä¯Ë˜>o˚ ^]s˚7#Åè≤˜å˜.âﬂäñÇö6¢˜|t6|Å8˚.˜q®êêß˜˜û~0ù§á˜#¸•WÄw’áò~C¸QC~~Aáw¯Ødãû¯Ì∂ü°˜gÒ˜|v¯„¯ÅÑ˜>¸ƒÑ˚>§˜°†õ˜¡¸í@~8àw˜∫ü8é~ó÷¯í¡˜†{˚°˚*†v›ﬂ¯çõ`çi°dº˚.˜V®¶ÔËΩÆÃâô˚_}ìêäãè¢äîáå~åÅÉÉ{|˚˚âç¯3ÜéOxzÜ>w{åòïãíØîZ¸uUââBÄ{˜~õMç~î¥˜Iç˜˚LûrçáãÖÉÇÖy{-ãû˜°≥˜Ω±xûÓÚ$Ò˜{˜⁄¯±¯w˜$—˚3˚öw’ÉìÇD¸FCäp9âw˜¨ü<å|ö’˜Hä§¢äû⁄≈ñ°≤»≠Æ«œ˚â!S\˚ÊzÅãçt˜ôßíë≠˜ÕY-˚*~∞¯‚‡Ÿ˜˘—¯J˘?ÇëyuÉáwã˚e˚˚Ääâäàãâáçâëä˜É˜5Y˚.&O?;uÑé´^°l}êpr}~tb∑u›˜5˜ Ú˜.˜@˚ƒ˚)¶µ‡˜Xúéåíé”ãûx∞¯·∞xûÚÒ¯˜ú˘?˜‚˜b˚)˜˚é˚†w’áò~C¸QC~~Aáw˜Ø˜Ç˜&˜˜cl˚Ö˚U#)˚a\~î´¯ê≠îë¡˜Q˜	˚˚L¸ív˘FwÇ˜∫˜±˘8I˚x˝FŒ”˚Fû˜Gw˘Ø≠˜¯?˜˘P˚Eù˚å=∂5˜ ˜2•Ú˜ã˜Eã˜_˚˜#˚Sã˚Tã˚˚#ã˚_ã˚¡˚‚SÆu©}•ÖπT=Õ˜_˜,íåãå≤˚¯ê˚T:˚	˚˚:˜	˜T˜R›˜˜˜ﬁ˚˚R˚—⁄˜ ˜o¯ﬁøh≤\jrskk¢wØîñèãìîåëÜäÅâhohVgïwŒ≠∏»≈˚*†v˜;À¯Qw˜∑⁄>ÿË¯k˜;À&¯Q_˚Œ¸QK˜≠˚;ÿ˜;<À˚Ñ˜Ç˜Èç˚*~•˘•£Î˜òÎ¯p˜ﬂ˜c˜E∆§ndò[[d~rnFPb˚˚˚≥˚—Or®≤~ªª≤ò§®—«≥˜˜+˚h`!44`ı˜h˜i∂ı‚‚∂!˚i˚*ôv¯Ë‘ü¯@¯T˘ö¸|_`%úÉ≤Ã¢õ¡ã˜m˚Z¸ËÃ˚*}ß¯∫˜Çö≠Á˜ë‰¯h˜m˜Bﬂ˚[wÑeL™˜1ÓÍ˜;´áö˚vá˚M˚;˚˚D‰˚˜˜·Í˜2j˚ cME4SÈ˜'≤ê≠îô°ò∑ù¥ÂæC˚˚*ã◊¯§‘˜Â·¯n˜~êmdÜpPã˚Ñ˜=˜D‚Ê≥⁄ã⁄Ì:Ÿ&˚HK˚lüÜØÍ≤Ø”ã›ƒP6?\*95˚F˚P~¯-ãû˜»µb¥˜ì≤xûÓ˜î¢¥¢œ¯µ¯úà˜#¸¶w’áò~C¸QC~~Aáw˜´ü@é{ö“˜p˜&âﬂäñÅö7¢˜|t6|Å8˚&˜q∑®êêß˜˜û~0ù˚*†v˜i·¯ö=åyñ∫¯ÌÇç˚G0~•ïúíúèîã¢ï}j¸m\yÄ=ä|˚*~ß˘ß√÷F’˜o–T◊‘¯Q˜0ÿiª˚ÊÿÓ¡ÆµŒﬁC≈#!;H0J¢iÒ4‰˚<ulG&ÿI˜	˜
ÿÕÚÿ1¯PuiCVTØEø‘ƒ∏≥ œ∂_G‰ô¸-G__IAU«›Œû±…æ™tîÑãËE£rN˜Éãû˘ûˆ∑¯ú˘ÔüFçyù–¯Q”ôô‘éü˚[˚o¸é˚{¯é˚Zw›Üò~D¸+&|x;Ñw˜}ü@éx•Ì¯$ç˜é¸∑ô˜ê¯Œç¸V9Ä~<Üw˚*}Ø¯Á∆˜—⁄g“–¯C˜lÍkπ+∑‡œπ§∞≈⁄K¬/,MX˚döá≥÷∏´ ãÃ∏^L^r_cnpwvÅWyû¡¶Üz™–ªp®XO8QICqvì†h£cÇéys}~ug∑v÷˜1˜Î˜˚ôív˘&û˜CÒ¯˘ü˚¥w⁄âô}C¸d\Äwq|Üë£Ñ≤|õqqutp_≤n∆˜ »”˜¯”ôô⁄ç”ïvñû˘û˜ ∏¯1∑x˘T˘ü˚~wÂÑëk4˚„â¸¯u˚?w∂åñÑµ[¸M%~y8Éw˜ü>éz£¯ç∏¯J¸πú¯§Ôöü⁄ëúãû˜¡§˜ÆØxûÒÒ˜}˜‹˘'üdçvóp¨˚b˜ë˜¢ƒ¿Ë˜/ ˚7˚ßw‘Üó~D¸D4ÖÑ=Éw˜®ü=íó“˜X√é˜Ç˚…N¯"Kc˚=ä˜äÏ®óíΩ˜≈]1dã≤dû˘ûÓ∞¯Ë˜Bs˚
Siz˚I0Åè∞¯n”òò’èü˚ßw’áò~C¸QpC~~Aáw¯≠¸˚Xv˘7w˜$Á8ﬂ˜U˘ßt¢pottop¢tß¶¢¢¶Ëå˝¯^ÜèXwXyWy|é©åãì¶î{_¸!Äjg}ÇêóÄ≥iÜéwwwywk≤t¬˜∆÷˜"˚*âw˜ó∂¯ß©Á˜ÄÔ+ÎÙ¯^¯!˜5/˜
˚˚4'˚ ˚
‘:ˆ¿ªù±π¯åàm˚%˚˚>qçw˜Öõ˜3˜<ã˜Ù+bváÇÅuod}j>\’˜˜± œ‰∏4˚;5ãÕ˜mÃ˜çÃ¯©˜ØÃ˚o˜2J˚2˚oJ˜o˚5Ã˜5˜o˚ØÕ¸ãI˜Kìvò™˜óÆö´˜g§œw»◊˜r§Ã÷˜q•¿˘ó˜ö—f≥H˚˚ ˚˚;ªW’ÛÎ˜˜˚¯2eYYbyDd{í†oür{ëo˚ ˚	˚BæQÕıÔ˜˜ôâñáûÉ£óâ£∑ßí†∞çâø¿˚˝∫¿¯Ö˜£˚:˚<du•∑œÀ˜?‚≤™f^¸˜º˚:˚<cu£∏»∞ÊπΩ£°°òúëçäÑíïÅöÑ®Éëéwã}5†v˜Õ˜Õ©¯ã¯©˜’Õ¸ãI¯ã˚]Õ¸ãI¸õv£v˜Û˜€˜ ˚˜h˜T¯)©r§lmrrml§r©™§§™∞ß¸øh≤\jrskl¢wØpïîéãîïêáÅäâiogVgïxŒ≠∏»ƒ˜∫ñv˘"ûê˙1˙6˘ü˚Zw¬ÜôÇl|ÑkÇs˚˚Ë˚˜Èp–ãäãó§°ï¬ü˚üw áèá≠:≠9 ˚Ø˚%¯É†àïãò°óë¿êü˚àw…Çéá“˚SÃ˚CçÜË˚°ö˜.¯;ëyë|éÇë|°U™;±*ú[™4ôŸ˜Éñ™Ã˜H¶‘ö≥ñ©öµõóªëúã∞fû˜»≥c≤˜ó±xû˜Ò˜Ü;˜¶Ä¯Â˜D≈oΩ\ßröyíZôçg Ë°≤∂⁄˜.«˚<˚¨wﬁàòA¸QA~8àw˜‚¶Ä˜%Ï“Ùß ˚˜Ã<Yb)äõ -ä˜yßèç√˜»]0¶Ä†˚»*O]˚O|ì¨˜ç˜Vå–d˚¸Ä˜˜ç˜‹˜˜T¯)©r§mlrrml§r™©§§™˚˝™r§mlrrlm§r™©§§©”ãû˘û˜œÒ˘R˘ü˚owæåùÇtÅáÄÅ{˚!˚x˚)˜tÄõÖöãò°ôëƒü˚¨wØâôÑßiüt≤W•e˜˚T˚M>~Ä2âw˜∆ü2ç~ñÿ˜U˜'˜w¡ﬂ®¢¬ë”ãû˘û˜Ò‡˘eüXzñÎ2˚|˜é˜Q˜Q««£óŒêü˚òw«áíàtrxs4:tu∫∂˚@˚0˜W‡ﬁñóŸëû˚¨xŸÖñ8¸;8Ä=Öx˜¨û=ëÄóﬁ˜D•°ı!ÿ>¿Fãt‡yÇàOâwdã±¯ﬂ±î¯ﬁ¯Á˜Dt˚hjq%˚ñ¯C¯ˆö¸°x˚>§Úü∞®˜˜q¸H¸ˆ|¯∆”ïv˘#ûõ˘;‡˘K˘ü˚`‡x∆ÜôÇm}Ñqm˚&¸˚,˜ÊmÕÅ©ãô§ñê èû˚ù‡wΩàú{±6˜ã¸∫ö˜p¯∆®’õõ∫ç˚b†v¯E˜ ∂˜ Ê˜ ¯2¯}´tügÅÅáãÉÇäÜêïçÆßÆ¿ØÅüHh^OQWÆd∫¨§£´˚{´tügÇÄáãÉÇäÖêåïçÆßÆ¿ØÅüHi^NQWÆd∫¨§£´˚b†v¯Õˆ©˜ Ê˜ ¯%¯›øh≤\jrskl¢wØïîéãîïêáÅäâiogVhïwŒ≠∏»ƒ˚{øh≤\jrskl¢wØïîéãîïåêÜäÅâiogVhïwŒ≠∏»ƒ˚bÑÛ¯π®˜MÛ´Ë¯2¯õÊ?Ã .EM9dút©•õõ§ôÖò}ö}õáíï©ª™ª∆∫UGb}PuVoIy`ÄXä\ùï÷ö©œ‡¿Õ¢Ωãº˚¸n®t¢nnttnn¢t®®¢¢®¸†v¯bwÉ˜r˚ﬂp ˜Ö¯è˚'˜)|ö}í|ãz}}zzî}û˜.*˚B¸è–˜êõKèÅñ”˜˜ÜèXyWxXx|é©åãì¶î{_˚{CÅGà{5†v˜pŒHÕ˜çÕ–¯©˜pŒ˚n˜pI∞˚q˚oI˜o˚pÕ˜pu°¯Wñ˜\öíã˜öî¸}é¶
ﬂ
_˜é˘
endstream
endobj
1 0 obj
<</OPM 1/Type/ExtGState>>
endobj
80 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
81 0 obj
<</OP false/OPM 0/op false>>
endobj
82 0 obj
<</A 83 0 R/Border[0 0 0]/Rect[243.612 9.0 285.357 16.0]/Subtype/Link/Type/Annot>>
endobj
83 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
74 0 obj
[84 0 R]
endobj
75 0 obj
<</Length 15161>>stream
1 g
/GS0 gs
0 783 0 0 re
f
0 0 0 0 k
/GS1 gs
50.5 36.5269 493 696.6661 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.007 Tc 0.007 Tw 10.5 0 0 10.5 50.5 726.0132 Tm
(thors concluded that there was no statistically significant)Tj
-0.02499 Tc 0.017 Tw 0 -1.23809 TD
[(change in QT)70 (c intervals from baseline, approximately 30%)]TJ
0.013 Tw 0 -1.2381 TD
(of the patients had noteworthy prolongation.)Tj
-0.024 Tc 0.02299 Tw 1 -1.22619 Td
[(In a prospective, open-label study)65 (, Straker et al. evaluat-)]TJ
-0.03101 Tc 0.01601 Tw -1 -1.22619 Td
[(e)-15 (d)-15 ( )-15 (t)-15 (h)-15 (e)-15 ( )-15 (e)-15 (f)5 (f)-15 (e)-15 (c)-15 (t)-15 (s)-15 ( )-15 (o)-15 (f)-15 ( )-15 (a)-15 (r)-15 (i)-15 (p)-15 (i)-15 (p)-15 (razole in the treatment of delirium in)]TJ
-0.015 Tc 0.00101 Tw 0 -1.22619 TD
(14 general medicine patients.)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 6 0 0 6 169.0108 664.6882 Tm
(7)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 0.00101 Tw 10.5 0 0 10.5 174.404 661.3882 Tm
(The mean age of the 6 men)Tj
-0.021 Tc 0.006 Tw -11.80038 -1.22619 Td
[(and 8 women was 70.9 \261)-220 (1)35 (1.3 years. Oral aripiprazole was)]TJ
-0.03 Tc 0.015 Tw T*
[(used, with a mean dose of 8.9 \261)-220 (3.5 mg per day)65 (. Changes in)]TJ
-0.024 Tc 0.009 Tw T*
(delirium rating scales were the primary outcome measures;)Tj
-0.015 Tc 0.061 Tw T*
[(QT)70 (c interval data were also assessed. Mean QT)70 (c interval)]TJ
-0.03999 Tc 0.017 Tw T*
[(length at baseline was 442 \261)-212 (44 msec. Follow-up ECGs were)]TJ
-0.015 Tc 0.02901 Tw 0 -1.22618 TD
(obtained in 10 of the 14 patients and revealed a mean de-)Tj
0.00999 Tw T*
[(crease of the QT)70 (c interval from 451 \261)-230 (50 to 434 \261)-229 (22 mil-)]TJ
-0.017 Tc 0.002 Tw 0 -1.22619 TD
[(liseconds. The authors mentioned that the QT)70 (c interval in-)]TJ
-0.035 Tc 0.02 Tw T*
[(creased in 3 patients; however)40 (, the degree of change was not)]TJ
-0.039 Tc 0.024 Tw T*
[(noted. While it was not the study\325)55 (s primary objective to eval-)]TJ
-0.01801 Tc 0.00301 Tw T*
(uate the cardiac safety of aripiprazole in delirious patients,)Tj
-0.028 Tc 0.013 Tw 0 -1.22618 TD
(there were no reports of TdP and aripiprazole demonstrated)Tj
-0.03999 Tc 0 -1.22619 TD
[(minimal ef)20 (fects on the QT)70 (c interval. )]TJ
-0.02499 Tc 0.022 Tw 1 -1.22619 Td
[(Given the lack of data associating aripiprazole with QT)70 (c)]TJ
-0.02299 Tc 0.02299 Tw -1 -1.22619 Td
(interval prolongation and the patient\325)Tj
-0.0229 Tc 14.05274 0 Td
(s)Tj
-0.02299 Tc 0.61603 0 Td
(response to quetiap)Tj
0 Tc 7.33174 0 Td
(-)Tj
-0.01401 Tc 0.013 Tw -22.00051 -1.2262 Td
(ine, aripiprazole was initiated for treatment of delirium in)Tj
-0.02499 Tc 0.004 Tw T*
[(our patient with schizophrenia. At the time of TdP)110 (, the only)]TJ
0 Tc 0.006 Tw T*
(other risk factor identified was concomitant famotidine.)Tj
-0.009 Tc 0.009 Tw T*
[(The prescribing infor)-25 (mation for famotidine states that, in)]TJ
-0.01601 Tc 0.01601 Tw T*
[(patients with renal impair)-25 (ment, QT)70 (c interval prolongation)]TJ
-0.00999 Tc 0.00999 Tw T*
[(occurs very rarely)65 (. Cases identified also indicate that sig-)]TJ
-0.01801 Tc 0.01801 Tw T*
[(nificant renal impair)-25 (ment is an important factor in famoti-)]TJ
-0.026 Tc 0.011 Tw T*
(dine-induced QT)Tj
-0.02631 Tc 6.35021 0 Td
(c)Tj
-0.026 Tc 0.65257 0 Td
(interval prolongation.)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0 Tw 6 0 0 6 209.0573 368.5632 Tm
(44,45)Tj
ET
BT
/T1_0 1 Tf
-0.026 Tc 10.5 0 0 10.5 224.2375 365.2632 Tm
(Finally)Tj
-0.02631 Tc 2.58434 0 Td
(,)Tj
-0.026 Tc 0.011 Tw 0.45859 0 Td
(in vitro)Tj
-0.01401 Tc 0.013 Tw -19.58936 -1.22619 Td
(and in vivo tests have concluded that famotidine does not)Tj
-0.015 Tc 0.015 Tw T*
[(af)20 (fect potassium channels responsible for cardiac repolar-)]TJ
-0.02499 Tc 0 Tw T*
(ization.)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 6 0 0 6 79.6339 329.9382 Tm
(46)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.02499 Tw 10.5 0 0 10.5 87.9641 326.6382 Tm
(Given that the patient had an estimated creatinine)Tj
0 Tc 0.073 Tw -3.56801 -1.22619 Td
(clearance greater than 60 mL/min, the literature would)Tj
-0.02499 Tc 0 Tw T*
(suggest that famotidine was less of a risk, if at all, contribu-)Tj
0 Tc 0.005 Tw T*
[(tory in our case. Further)-25 (more, our patient was receiving)]TJ
0.073 Tw T*
(famotidine both before and after aripiprazole use, with)Tj
-0.02499 Tc 0.013 Tw T*
(documented QT)Tj
-0.0251 Tc 6.08739 0.00001 Td
(c)Tj
-0.02499 Tc 0.6563 0 Td
[(intervals within nor)-21.8 (mal limits. )]TJ
-0.01801 Tc 0.01801 Tw -5.7437 -1.2262 Td
(One additional consideration when evaluating the asso-)Tj
-0.02 Tc 0.02 Tw -1 -1.22619 Td
(ciation between aripiprazole administration and TdP is the)Tj
0 Tc 0 Tw T*
(nor)Tj
0.123 Tw 1.35767 0.00001 Td
[(malization of QT)70 (c interval upon withdrawal of the)]TJ
-0.009 Tc 0.009 Tw -1.35767 -1.2262 Td
(drug. After the occurrence of TdP and discontinuation of)Tj
-0.01601 Tc 0.01601 Tw T*
[(aripiprazole, the patient\325)55 (s QT)70 (c interval retur)-25 (ned to nor)-25 (mal)]TJ
-0.02499 Tc 0.021 Tw T*
[(over 14 days, which is possibly related to the 75)-25 (-hour half-)]TJ
-0.024 Tc 0.024 Tw T*
(life of the agent.)Tj
ET
BT
/T1_1 1 Tf
-0.022 Tc 0 Tw 6 0 0 6 115.5158 175.4381 Tm
(42)Tj
ET
BT
/T1_0 1 Tf
-0.024 Tc 0.024 Tw 10.5 0 0 10.5 123.8526 172.1381 Tm
(This would further suggest that aripipra-)Tj
-0.02499 Tc 0.021 Tw -6.98596 -1.22619 Td
[(zole was the precipitating factor for QT)70 (c interval prolonga-)]TJ
0.013 Tw T*
(tion and TdP in this case. )Tj
-0.015 Tc 0.015 Tw 1 -1.22619 Td
[(T)70 (o our knowledge, this is the first reported case of TdP)]TJ
-0.013 Tc 0.013 Tw -1 -1.22619 Td
(associated with aripiprazole therapy)Tj
-0.01331 Tc 13.90639 0.00001 Td
(.)Tj
-0.013 Tc 0.4866 0 Td
(Clinicians should be)Tj
-0.015 Tc 0.015 Tw -14.393 -1.2262 Td
[(aware that low-)-75 (dose aripiprazole may produce significant)]TJ
-0.00999 Tc 0.00999 Tw 0 -1.2262 TD
[(QT)70 (c interval prolongation and TdP in patients with mini-)]TJ
-0.024 Tc 0.024 Tw T*
(mal risk factors. Since aripiprazole may be selected for pa-)Tj
-0.022 Tc 0.022 Tw T*
[(tients with a history of QT)70 (c interval prolongation or a high)]TJ
-0.00301 Tc 0.00301 Tw T*
(baseline interval, more cardiac data are needed to assess)Tj
-0.02499 Tc 0.013 Tw T*
(the safety of the drug in this population.)Tj
ET
BT
/T1_2 1 Tf
0.007 Tc 0.007 Tw 8.5 0 0 8.5 309 726.999 Tm
(Sarah Nelson)Tj
ET
BT
/T1_3 1 Tf
0.0069 Tc 0 Tw 8 0 0 8 366.423 726.999 Tm
(P)Tj
0.007 Tc 0.007 Tw (harmD BCPS, Critical Care Clinical Pharmacist,)Tj
-0.00011 Tc -7.17787 -1.125 Td
(M)Tj
0 Tc -0.01401 Tw [(ayo Clinic, Rochester)55 (, MN)]TJ
ET
BT
/T1_2 1 Tf
-0.0231 Tc 0 Tw 8.5 0 0 8.5 309 706.999 Tm
(J)Tj
-0.02299 Tc -0.005 Tw (onathan G Leung)Tj
ET
BT
/T1_3 1 Tf
8 0 0 8 382.3974 706.999 Tm
[(PharmD BCPS BCPP)129 (, Psychiatric Clinical Phar)-1 (-)]TJ
0 Tc -0.01401 Tw -9.17467 -1.125 Td
(macist, Mayo Clinic, Rochester)Tj
ET
BT
/T1_2 1 Tf
0 Tw 8.5 0 0 8.5 309 686.999 Tm
(Correspondence:)Tj
ET
BT
/T1_3 1 Tf
-0.01401 Tw 8 0 0 8 381.4669 686.999 Tm
[(Dr)55 (. Nelson, nelson.sarah3@mayo.edu)]TJ
ET
BT
/T1_2 1 Tf
-0.03101 Tc -0.007 Tw 8.5 0 0 8.5 309 675.999 Tm
(Reprints/Online Access:)Tj
ET
BT
/T1_3 1 Tf
0 Tw 8 0 0 8 403.062 675.999 Tm
[(www)55 (.theannals.com/cgi/reprint/aph.1R387)]TJ
ET
BT
/T1_2 1 Tf
0 Tc -0.01401 Tw 8.5 0 0 8.5 309 660.999 Tm
(Conflict of interest:)Tj
ET
BT
/T1_3 1 Tf
8 0 0 8 388.7657 660.999 Tm
(Authors reported none)Tj
-9.97071 -1.87501 Td
(\251)Tj
-0.00999 Tc -0.01801 Tw 0.97688 0.00001 Td
(1967-2013 Harvey Whitney Books Co. All rights reserved. No part)Tj
0.00301 Tc 0.011 Tw -0.97688 -1.12501 Td
(of this document may be reproduced or transmitted in any form or)Tj
0.009 Tc 0.005 Tw 0 -1.125 TD
(by any means without prior written permission of Harvey Whitney)Tj
-0.017 Tc -0.011 Tw T*
(Books Co. For reprints of any article appearing in )Tj
ET
BT
/T1_4 1 Tf
8 0 1.70046 8 477.4647 618.9989 Tm
(The Annals)Tj
ET
BT
/T1_3 1 Tf
-0.01669 Tc 0 Tw 8 0 0 8 516.508 618.9989 Tm
(,)Tj
-0.017 Tc 0.51144 0 Td
(please)Tj
0 Tc -0.01401 Tw -26.44993 -1.125 Td
(contact 415sales@hwbooks.com)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0 Tw 10.5 0 0 10.5 309 581.999 Tm
(References)Tj
ET
BT
/T1_0 1 Tf
-0.009 Tc 0.009 Tw 8 0 0 8 312.9293 564.124 Tm
[(1.)-491 (Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for\)]TJ
-0.02499 Tc 0.005 Tw 1.19634 -1.23437 Td
(the sustained use of sedatives and analgesics in the critically ill adul\t. Crit)Tj
0.013 Tw 0 -1.23437 TD
[(Care Med 2002;30:1)35 (19)-25 (-)-125 (41. )]TJ
0 Tc 0.08701 Tw -1.1875 -1.35938 Td
[(2.)-500 (Skrobik YK, Ber)20 (geron N, Dumont M, Gottfried SB. Olanzapine vs)]TJ
-0.00101 Tc 0 Tw 1.1875 -1.23437 Td
(haloperidol: treating delirium in a critical care setting. Intensive Car\e)Tj
-0.02499 Tc 0.013 Tw 0 -1.23438 TD
[(Med 2004;30:444)-75 (-9. doi: 10.1007/s00134)-75 (-)-100 (003)-24 (-)-25 (21)35 (17-)-100 (0)]TJ
-0.017 Tc 0.017 Tw -1.204 -1.35938 Td
[(3.)-483 (Devlin JW)90 (, Roberts RJ, Fong)-1 ( JJ, et al. Ef)21 (ficacy and safety of quetiapine)]TJ
-0.02499 Tc 0.01199 Tw 1.204 -1.23438 Td
[(in critically ill patients with delirium: a prospective, multicenter)40 (, random-)]TJ
-0.01401 Tc 0.01401 Tw 0 -1.23437 TD
[(ized, double-blind, placebo-controlled pilot study)65 (. Crit Care Med 2010;)]TJ
-0.02499 Tc 0 Tw 0 -1.23438 TD
(38:419)Tj
0.013 Tw 2.65272 0 Td
[(-)-25 (27. doi: 10.1097/CCM.0b013e3181b9e302)]TJ
-0.022 Tc 0.022 Tw -3.86211 -1.35938 Td
[(4.)-478 (Girard TD, Pandharipande PP)110 (, Carson SS, et al. Feasibility)65 (, ef)20 (ficacy)65 (, and)]TJ
-0.01601 Tc 0.01601 Tw 1.20939 -1.23438 Td
(safety of antipsychotics for intensive care unit delirium: the MIND ran-\)Tj
-0.02499 Tc 0.013 Tw 0 -1.23437 TD
[(domized, placebo-controlled trial. Crit Care Med 2010;38:428)-25 (-)-25 (37. )]TJ
0 -1.23438 TD
(doi: 10.1097/CCM.0b013e3181c5871)Tj
0 Tc 0.089 Tw -1.1875 -1.35938 Td
[(5.)-500 (Boettger S, Friedlander M, Breitbart W)90 (, Passik S. Aripiprazole and)]TJ
-0.021 Tc 0.021 Tw 1.1875 -1.23438 Td
[(haloperidol in the treatment of delirium. Aust N Z J Psychiatry 201)35 (1;45:)]TJ
-0.02499 Tc 0.013 Tw 0 -1.23437 TD
[(477-)-25 (82. doi: 10.3109/00048674.201)35 (1.54341)35 (1)]TJ
0 Tw -1.2125 -1.35938 Td
(6.)Tj
0.019 Tw 1.17499 0 Td
(Boettger S, Breitbart W)Tj
-0.0251 Tc 8.88832 0 Td
(.)Tj
-0.02499 Tc 0.46874 0 Td
(An open trial of aripiprazole for the treatment of)Tj
0.009 Tw -9.31955 -1.23438 Td
[(delirium in hospitalized cancer patients. Palliat Support Care 201)35 (1;9:351)50 (-)]TJ
0.013 Tw 0 -1.23438 TD
[(7. doi: 10.1017/S147895151)35 (1000368)]TJ
-0.004 Tc 0 Tw -1.19176 -1.35937 Td
(7.)Tj
0.004 Tw 1.23724 0 Td
[(Straker DA, Shapiro P)96.7 (A, Muskin PR. Aripiprazole in the treatment of)]TJ
-0.02499 Tc 0.013 Tw -0.04547 -1.23438 Td
(delirium. Psychosomatics 2006;47:385)Tj
0 Tw 14.73115 0 Td
(-91.)Tj
-0.024 Tc -15.9426 -1.35938 Td
(8.)Tj
0.024 Tw 1.17815 0 Td
(Alao AO, Moskowitz L. Aripiprazole and delirium. Ann Clin Psychiatry)Tj
-0.02499 Tc 0.013 Tw 0.0333 -1.23438 Td
(2006;18:267-9. doi: 10.1080/10401230600948506)Tj
-0.022 Tc 0.022 Tw -1.20958 -1.35938 Td
[(9.)-478 (Alao AO, Soderber)20 (g M, Pohl EL, Koss M. Aripiprazole in the treatment)]TJ
-0.02499 Tc 0.013 Tw 1.20958 -1.23437 Td
(of delirium. Int J Psychiatry Med 2005;35:429)Tj
0 Tw 17.55442 0 Td
[(-)-25 (33.)]TJ
0.011 Tw -19.24192 -1.35938 Td
[(10.)-475 (Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for)]TJ
0.013 Tw 1.6875 -1.23438 Td
[(the treatment of delirium. Psychosomatics 2004;45:297-)-25 (301.)]TJ
-0.019 Tc 0.019 Tw -1.6875 -1.35938 Td
[(1)35 (1.)-482 (Miyaji S, Y)100 (amamoto K, Hoshino S, Y)100 (amamoto H, Sakai Y)130 (, Miyaoka H.)]TJ
0 Tc 0.136 Tw 1.6875 -1.23437 Td
(Comparison of the risk of adverse events between risperidone and)Tj
-0.036 Tc 0.02 Tw T*
[(haloperidol in delirium patients. Psychiatry Clin Neurosci 2007;61:275)-24 (-)-26 (8)-1 (2)-1 (.)]TJ
-0.02499 Tc 0 Tw 0 -1.23437 TD
[(doi:10.1)35 (1)35 (1)35 (1/j.1440)-75 (-1819.2001.01655.x)]TJ
-0.009 Tc 0.009 Tw -1.6875 -1.35938 Td
[(12.)-491 (Kim SW)90 (, Y)100 (oo JA, Lee SY)131 (, et a)-1 (l. Risperidone versus olanzapine for the)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.23437 Td
[(treatment of delirium. Hum Psychophar)-19 (macol 2010;25:298)]TJ
0 Tc 22.42262 0.00002 Td
(-)Tj
-0.02499 Tc 0 Tw [0.3 (302. )]TJ
0.013 Tw -22.42263 -1.23439 Td
(doi: 10.1002/hup.1)Tj
-0.06 Tc 0 Tw 7.11081 -0.00001 Td
[(11)-35 (7)]TJ
-0.019 Tc 0.019 Tw -8.79831 -1.35937 Td
[(13.)-481 (Mittal D, Jimerson MA, Neely EP)110 (, et al. Risperidone in the treatment of)]TJ
1.6875 -1.23437 Td
(delirium: resulting from a prospective open-label trial. J Clin Psychiat\ry)Tj
-0.02499 Tc 0 Tw T*
(2004;65:662-7. )Tj
-0.017 Tc 0.017 Tw -1.6875 -1.35938 Td
[(14.)-483 (Liu CY)130 (, Juang YY)130 (, Liang HY)131 (, Lin NC, Y)100 (eh EK. Ef)20 (ficacy of risperidone)]TJ
-0.013 Tc 0.013 Tw 1.6875 -1.23438 Td
(in treating the hyperactive symptoms of delirium. Int Clin Psychophar-)Tj
-0.02499 Tc T*
[(macol 2004;19:165)-25 (-)-25 (8.)]TJ
0 Tc 0 Tw -1.6875 -1.35938 Td
(15.)Tj
0.13 Tw 1.75 0.00001 Td
[(Grover S, Kumar V)130 (, Chakrabarti S. Comparative ef)20 (ficacy study of)]TJ
-0.009 Tc 0.009 Tw -0.0625 -1.23438 Td
(haloperidol, olanzapine, and risperidone in delirium. J Psychosom Res)Tj
-0.02499 Tc 0 Tw 0 -1.23438 TD
[(201)35 (1;71:277-)-25 (81.)]TJ
-0.00101 Tc 0.00101 Tw -1.6875 -1.35938 Td
[(16.)-499 (Horikawa N, Y)100 (amazaki T)75 (, Miyamoto K, et al. T)35 (reatment for delirium)]TJ
-0.024 Tc 0.024 Tw 1.6875 -1.23437 Td
(with risperidone: results of a prospective open trial with 10 patients. \Gen)Tj
-0.02499 Tc 0.013 Tw 0 -1.23437 TD
[(Hosp Psychiatry 2003;25:289)-25 (-92.)]TJ
-0.007 Tc 0.007 Tw -1.6875 -1.35938 Td
[(17.)-493 (Parellada E, Baeza I, de Pablo J, Martinez G. Risperidone in the treat-)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.23438 Td
[(ment of a patient with delirium. J Clin Psychiatry 2004;65:348)-25 (-53.)]TJ
0 Tc 0.006 Tw -1.6875 -1.35938 Td
[(18.)-500 (Lacasse H, Perreault MM, W)40 (illiamson DR. Systematic review of an-)]TJ
-0.022 Tc 0.022 Tw 1.6875 -1.23437 Td
(tipsychotics for the treatment of hospital-associated delirium in medica\l-)Tj
-0.02499 Tc 0.013 Tw T*
[(ly or sur)20 (gically ill patients. Ann Phar)-25 (macother 2006;40:1966)-25 (-73.)]TJ
ET
0 0 0 0 k
309 740.1929 234.5 10 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
8 0 0 8 333.0128 744.7228 Tm
[(T)90 (orsades de Pointes After Administration of Low-Dose Aripiprazole)]TJ
ET
0 0 0 0 k
157.5 15.444 386 13.08 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
10 0 0 10 260.0963 21.6856 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_7 1 Tf
0 Tc 0 Tw 5 0 0 5 393.2213 23.1856 Tm
(n)Tj
ET
BT
/T1_6 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 406.4024 21.6856 Tm
[(2013 February)55 (, V)110 (olume 47    )]TJ
ET
BT
/T1_7 1 Tf
0 Tc 0 Tw 5 0 0 5 516.9322 23.1856 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 10 0 0 10 530.1133 21.6856 Tm
[(e1)57 (1)]TJ
ET
0 0 0 0 k
50.5 16.524 79.5 11.669 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
-0.02499 Tc 10 0 0 10 50.5 21.3551 Tm
(theannals.com)Tj
ET
BT
0 g
/GS2 gs
/T1_8 1 Tf
0 Tc 5 0 0 5 284.35733 11 Tm
( at UNIV CALGARY LIBRARY on May 25, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
36 0 obj
<</BaseFont/ITLCLN+Helvetica-Bold/Encoding 33 0 R/FirstChar 32/FontDescriptor 35 0 R/LastChar 117/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 0 0 722 722 722 722 667 0 778 0 278 556 0 611 833 722 778 0 0 722 667 611 722 667 0 0 667 0 0 0 0 0 0 0 556 0 556 611 556 333 611 611 278 0 0 278 0 611 611 611 0 389 556 333 611]>>
endobj
12 0 obj
<</BaseFont/QZOEKJ+Helvetica/Encoding 9 0 R/FirstChar 32/FontDescriptor 11 0 R/LastChar 169/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 278 333 278 278 556 556 556 556 556 556 556 556 556 556 278 278 0 0 0 0 1015 667 667 722 722 0 611 778 722 0 500 0 556 833 722 778 667 778 722 667 611 0 0 944 0 0 0 0 0 0 0 0 0 556 556 500 556 556 278 556 556 222 222 500 222 833 556 556 556 556 333 500 278 556 500 722 500 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 737]>>
endobj
40 0 obj
<</BaseFont/DXOVRD+Helvetica-Oblique/Encoding 37 0 R/FirstChar 32/FontDescriptor 39 0 R/LastChar 116/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 611 0 0 0 0 0 0 0 0 0 0 0 0 556 0 500 0 556 0 0 556 0 0 0 222 833 556 556 0 0 333 500 278]>>
endobj
37 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 46/period 65/A 80/P 84/T 97/a 99/c 101/e 104/h 108/l/m/n/o 114/r/s/t]/Type/Encoding>>
endobj
39 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-214 -224 1198 931]/FontFile3 38 0 R/FontName/DXOVRD+Helvetica-Oblique/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
38 0 obj
<</Length 1388/Length1 1388/Subtype/Type1C>>stream
  DXOVRD+Helvetica-Oblique   E¯ ¯¯¯¯˚:˚t˙|˙7
 ã
 o
 ãã      ¸  !¨  K Äà002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki    " O  1 I B S N D P U F M T  5    < ~ Å √ ˝â¬!s∫ÎH]◊Áú†v˜d‚¯:wô˘˘ ˚ò˘a˚˚†˝aÓ÷˜d˜≥“˚d!˜ª˚r˜˜–ç-†v¯^€|wÃﬁ8‰˜è‚Ù¯Ä˜˜˜IŒ˚EZpM_âÙ’8¸üÏ‰˜∞˜¿ÃÂ’≠`.˚÷¸ú†v˜¬ﬁ˜é›·Ì˜ÁÓ˘¯ò˜6€˚˚◊˝aÌ˜¬˜u˜··˜(â6Y_+˚U˜é˜XÈºb;-†v¯_€˜FwÃ„˜è‚¯˜˜˜
KÕ˚HbtLYâ˜ú3˝a„˜±˜¬ Î–™f:˚È-|‘[v˜âÕ˜8‘Ø‰L€˜Ö„6‡µ¯§Àá~ÉäÑvÉî°˜¡Ê@¬˚˚HT˚
Ñ€—ï∞©Ÿ÷∑kSi{wlá˚$yπ$~SQ.0ÕOÌ◊√§«ƒˆQë§t√ûñçî°∫˚%˜HK>Q5Qf´ø¿Ø©ÿî˜òÜä≥ü˚—†v¯PÈ|wÿ›9„˜ﬂ¯PÊç~ÑåáQamB]â„9¸üË„˜ƒ‹√∆Ÿ˜K†v¯_⁄|wÃﬁ8„˜q„˜n„ˆ˘î˜˛˜KŒ%Lp|EJ≈o^¶IGYoNcâˆ’8¸üÓ„˜±Ù¡–ﬂæ´fO˚˛„˜”Ÿ¡…ŒÃ´c:˚Ê˚*{ÿ¯"⁄©È˜†‡7ﬂË¯q˜L7<y]_I1Z“˜˜¬’Áœ±h>ö‡˜}GÃ˚˚)*˚˚?˚8Á ˜"˜€÷˜ô-}◊¯$◊ÆÊ˜ƒÊ¯ù˜ö˜7'˜˚#˚#'˚˚7˚8Ó˚˜$˜$Ó˜˜80˚P=..PŸ˜˜∆ŸËË∆=˚¸Ñ◊¯’ﬂ„˜ï–mezó®˜Áﬂ’7˜&3˚&EA—˚Ï?¨g–úôåë≥-|◊˜@—˜/€≥Ë˜¥‚8ÊÙ¯ò˜}˜V:˜˚%˚1.˚ ˚K˚6Á'˜*¯˜ÿ»˜
ß4J{YeC.W√˜ÜÙ˜∏—˚∏Ïî«≈›Ô∞@;è¸@†v˘awŒ„˜/˘a3˝a˚*|÷˜2ŸV÷˜$◊´ﬂGﬂ˜y‡D„’¯c˜2‘c± ¶ˆ4°<üyòã±∑µ® ‹±pNê‡˜ ÇF√˚˚=J%I≥a›wŸrﬁv†}ãdW]k@2d©ŸÅ7éTíqùp´\”oÊã˜ãﬁ–ãÛ¸ãı‚Û˜Sı#!d†v˘‡˜ïÎ¯Á˘‡¸Ÿ6˜á˝Î˘u°¯üö˜)õôü˜°ñ¸}ö◊
„
_˜™˘
endstream
endobj
9 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon 64/at/A/B/C/D 70/F/G/H 74/J 76/L/M/N/O/P/Q/R/S/T 87/W 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 169/copyright]/Type/Encoding>>
endobj
11 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-166 -224 1000 931]/FontFile3 10 0 R/FontName/QZOEKJ+Helvetica/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
10 0 obj
<</Length 5282/Length1 5282/Subtype/Type1C>>stream
  QZOEKJ+Helvetica   @¯ ¯¯¯¯˚:˚t˙|˙7
 ãã
 ãã   Û   Ô  v¨  Å Äà002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki  @  ) 4 B S I  / F M T P O  + U ( - V H 5 E D J C G Q 	 1 
 X [  "    Z N L W ' R  2    % K $    0   3  Y ™  8 # ! . B   1 ≤>w±¥ﬂ<QÀTÉ∑ËRiß)F•˜s¨Iã«,<v´			i	»	˚
#
F
•
ÏX|”Mí»%^ó¥}ò˙z∑I¡q(É”†v˜·‚˜ΩwÿÏ*Ì¯
ÏÙ˘˘a*˚Ω¸˜Ω*˝aÏÌ˜·¯
˚·úxﬁ˜ãŸ`Â˜nﬁºÊGË˜ÍÊCË’¯ˇ˜YÔQœ#£ˆ˚a∫Qòn¨ãΩ÷ ∫˜«Z*îÊ˜/Ä3’˚B˚2,7˚3øSÒsŸ˜&h˜
oØpãN4L_˚˚D∆ˆà0åçDïe©dGøŸi˜ ˜Kˆ€˜-|‘[v˜âÕ˜8‘Ø‰L€˜Ö„6‡µ¯§Àá~ÉäÑvÉî°˜¡Ê@¬˚˚HT˚
Ñ€—ï∞©Ÿ÷∑kSi{wlá˚$yπ$~SQ.0ÕOÌ◊√§«ƒˆQë§t√ûñçî°∫˚%˜HK>Q5Qf´ø¿Ø©ÿî˜òÜä≥ü˚—†v¯PÈ|wÿ›9„˜ﬂ¯PÊç~ÑåáQamB]â„9¸üË„˜ƒ‹√∆Ÿ-†v¯_€˜FwÃ„˜è‚¯˜˜˜
KÕ˚HbtLYâ˜ú3˝a„˜±˜¬ Î–™f:˚È¸”†v˘aw◊Ë¯Í˘˘a,¸◊â˚˙¯◊˚˝aË¯ÿç¯¸ÿ-|◊˜@—˜/€≥Ë˜¥‚8ÊÙ¯ò˜}˜V:˜˚%˚1.˚ ˚K˚6Á'˜*¯˜ÿ»˜
ß4J{YeC.W√˜ÜÙ˜∏—˚∏Ïî«≈›Ô∞@;è¸@†v˘awŒ„˜/˘a3˝a˚*|÷˜2ŸV÷˜$◊´ﬂGﬂ˜y‡D„’¯c˜2‘c± ¶ˆ4°<üyòã±∑µ® ‹±pNê‡˜ ÇF√˚˚=J%I≥a›wŸrﬁv†}ãdW]k@2d©ŸÅ7éTíqùp´\”oÊã˜ãﬁ–ãÛ-}◊¯$◊ÆÊ˜ƒÊ¯ù˜ö˜7'˜˚#˚#'˚˚7˚8Ó˚˜$˜$Ó˜˜80˚P=..PŸ˜˜∆ŸËË∆=˚-†v¯^€|wÃﬁ8‰˜è‚Ù¯Ä˜˜˜IŒ˚EZpM_âÙ’8¸üÏ‰˜∞˜¿ÃÂ’≠`.˚÷¸ãı6v‚ÛXæ–˜SìÌ‡#!–¿‡äHscÅ]”õ´ªÊ˚*x›˘"wúÂ˜sÏ¯?˜V¯ü*¸•7fb>Bg≤⁄Ω1D˚ÿG˜˜÷Ÿ˜¸Ñ◊¯’ﬂ„˜ï–mezó®˜Áﬂ’7˜&3˚&EA—˚Ï?¨g–úôåë≥˜xﬁ`v˜¡ﬁ˜ü‡ªÔ¯eÂ|˘S¯˚Œ8˜tà@Ågqf¸PcJm8˚09Ò˜V˜EÈ˜˜'˜ –Y&´Ë˜(o˚„˚7˚b˚˚,˚˚o˜˚)˜TˆÿÆÿ…|£.-ã·˘w◊Ï¯¨·˚ˇ˘*˝a-|◊cv¯üwœ‚˜â„8ﬁÙ¯|¯ü¯3˚¥ TH2Hi≤◊˜Ô4¸%…Oˆ€¥¢—∏Ùç=-˚n”˜◊¯!€|w≥Ê@„˜ü„7ﬂ9›‘Ä¯á∂¯t9@˘ âÃ^^§H˚4"˚0˚D‰˚˜“µ†¿´ˆ çu˚cZ˚Hg§ƒ}3"úÕZ˜˜7’›˜G˘ 7˜b˚WH/5Uÿ˜˜ªŒÁÈΩC˚d†v˘‡˜ïÎ¯Á˘‡¸Ÿ6˜á˝Î˘-|◊cv¯_Ÿ˜HwÆÂ˜±„4‚:‹y¯Ü˘a˙4˚°âŒ[d°E˚7&˚5˚E‰˚˜!œªß≈≠yçD¸Ñ˜â˚TD24Uÿ˜˜∫ÀÍÊø>˚˚*{ÿ¯"⁄©È˜†‡7ﬂË¯q˜L7<y]_I1Z“˜˜¬’Áœ±h>ö‡˜}GÃ˚˚)*˚˚?˚8Á ˜"˜€÷˜ô¸@†v¯üw˜ÌŒ„˜/¯ˇÌ3)„¸ˇ¯ü3¸ü-{ÿcv¯`Ÿ˜Gw≈„3ﬂ˜±Âz¯ô˜®˜24Û˚MZqTcâ˜ò3˝aﬁÃçˆN∏ØwŒ˜Â˜˜D1É˚W?13T“˜˜Ω◊ÊÍºI˚¸†v¯U’˜awﬂ„˜ò¯U’3Ã∂õû∞ìîäâù⁄åwÄåÇ/_f=1EA—¸U„¯U-˚Lv˜R◊¯#⁄{w≈ﬁ8„3ﬂ˜±ÂÈ¯ô˜®˜24Ù˚H^qL`â˘‘8˝lÂ„˜òçWµÆy»˜#„˜˜H1Ö˚X?0„2U–˜˜!º’ÁÍºJ˚˚—˚Mv˙>wœË˜ø˚b<˜2P˜˜J˜D≥˜Î˜;O˚˚B]˚˚=˚V—˚Ú˚0ú†v˜¬ﬁ˜é›·Ì˜ÁÓ˘¯ò˜6€˚˚◊˝aÌ˜¬˜u˜··˜(â6Y_+˚U˜é˜XÈºb;˚—˚Nv˙>w˜@Ë˜ù˜ù˜VE˜$˜0Q⁄˚2∆˚˚J˚Dc˚+˚;«˜˜Bπ˜˜=”†v¯üwõ˘I˘Y¯ü4 ¸.â&¯.)&¸.â'¯.,˜+¸üÂÒ¯)çÙ¸)Ê˚*ã”¯’™¯I¯h”˚’˜Õ¯’¸)A˜∂˚Œ¸F¸ãı‚Û˜Sı#!ú†v˜d‚¯:wô˘˘ ˚ò˘a˚˚†˝aÓ÷˜d˜≥“˚d!˜ª˚r˜˜–ç-†v˜>◊¯]w˜ﬂ„¯ù˜>◊%¯]B˚’¸R4˜∆˚>„˜>3◊˚u˜t˜‘å-ã›¯±⁄•Ó:‚˜ØÁË¯é›¸òÀª≥∆´‘≥Ô¬„º˜˜3ﬁ˚ÿ˚3?$˚)‚˜ë∏¡Â‡ƒW=Dmk&Q/VË˚Fc5Ö˚˚—†v˜{Â∑˜à˜¥˜{Â˚à1˚*˚j⁄˘&wñ¯q¯|¯ü+˚!¸?â˚¯?(˜V¸¨b˚Çdãv|éëv<ÖõóàúÚõ†˜_ÿÔ˜úêñﬁ˜Ç˜K†v¯_⁄|wÃﬁ8„˜q„˜n„ˆ˘î˜˛˜KŒ%Lp|EJ≈o^¶IGYoNcâˆ’8¸üÓ„˜±Ù¡–ﬂæ´fO˚˛„˜”Ÿ¡…ŒÃ´c:˚Ê˚*†v¯üw˜jwŒ‡¯â˚h˜€˜\˜X˚˚v˚q¯36˝a‡˜Z‘Õ˜7˚ú˚*†v¯üwì¯w¯¯ü+˚(¸=âä˚¯>'˜R¸üËd†v˜Ÿ·˜p··Ï¯⁄˘·¸Ñ˝aÏ˜Ÿ˜Ù·˚Ù˜p-˚Nv˜T◊¯"⁄|wÆÊ˜≠‚7ﬂ8ﬁŸ¯Ç˚c˘n8Aâ¸…a\¶G˚4"˚1˚G„˚˜!»≥üº≥ç˚ô˙é¯Y˚UF14Vÿ˜˜∫ÕÁÈæA˚-w€¯«⁄∞Ë˜∫Ë¯ô˜È˜}6˜˚/˚/6˚˚}˚z‚˚˜-˜-‚˜˜z.˚KX)++XÌ˜K˜OΩÍÏÏΩ+˚N˜x‚¯‹‡≤Ó¯âÓ˘v˜˚˜u˚!˜-˚d˚e˚!˚-˚u˚v˜ ˚,˜f”√ö¨√˜6º≈)÷—÷≠Ëã˜(/o>WU1—ZO’Ra{qÜeã˚(%˜
˜A˜DÔ˜	˜+˜*Ô˚	˚D-†v¯Ü“˜w˜úÍ¯Ü˜7¸ÜÍ˘REp$qx˚Ä-x◊˜–⁄˜*·´Â˜ΩË¯î˜x˜(Î˚Tfk^™˜V˜Ω·˚ˇW¸÷ÜµºÆù¿ãÊÃK1*LJ/;\≤Ÿ|1˚ú◊K˜˜1ÏÈ˜--x⁄˜ú‘˜w⁄≠Á˜™ÂIÈÙ¯û˜bﬁiª8≠ç¯√†¨øŒ˜6’˚˚(FD˚3É·˜ ì≤∂„›Ω`DAYd,~Öãçz?åõìãéÙ˜¬c39MU+*`π˜á/˚6ô”C˜(˜/Ó„˜”ã›¯Ω›‹Ì¯Ó˘5¯˜g˚˜˚J˚∑˝a˜≥˜R˜˜˜z(Ö˚A< ˚˚O¯Ω˜I˜5¿˚˚¸@˚eŸ˘"w˜ÌŒ„˜/¯ˇÌ3)„˝L¯Ï3¸‚UÅÅTyAáúêãöË¥¥Ê”w·¯›‡∑Ó¯HÁ5ÈË˘;˜ú-˚qCH˚˚&8˜˜R˜GÁˆ˜+ÔœV*§Á˜*s!‡˚7˚a˚˚%˚x˚Ç˜˚%˜\Ë˜?˜	ı˜F§¸†v¯/ı‚ÛXæ–˜S¯/ı‡#!Û¸'Ì#!–¿‡äHscÅ]”õ´ªÊ-†v¯Ì·˜Í¯û¯ˆÿ¸y5¯@1W:U˚O˚l/}#Í≠˜4¢“¡˜ ƒ˜¿⁄–ÿ¸ãı˜≈ı‚Û˜S¯/ı#!Û¸/ı#!˜x‚¯‹‡≤Ó¯âÓ˘v˜˚˜u˚!˜-˚d˚d˚"˚-˚u˚v˜ ˚,˜f˜e˜ ˜,˜v(˚A%˚
˚(˚)%˜
˜A˜EÔ˜˜+˜*Ô˚	˚D-x‘˜I⁄˜ÀŸµÂ9‚˜¶Ò4‚Ú¯ï¯˜k7˜˚6˚1+˚%˚‡2˜Ÿ¡¶ƒÆçân˚X`H)ãÍEa¥’Ñ4˚î‘I˜÷∆®≈µΩŒ®˜˜Ù%Ì#XR.6Y¡ÁÒø ﬂ‚√P0¸çv˘áwz˜Ã˜ª˘tI˚ä˝áŒ”†v˜«ﬁ˜ä‹„Î¯Ó˘>õoöÖóâ∏Ö˜á◊y©Kß÷π§∂ã‡ã˜6–˚*ã˚ﬂ˝aÎ˜«˜ÊÆi.çé˚å}òRÇ¯ô6[a*˚v˜ä˜áﬁ∏a>-x⁄˜¢◊˜oŸ±ËEÊ˜åÊGËÍ¯ò˜`Ÿh¿;≤ÏÀ¨•¥Œ˜5’˚˚7?˚I®aÕmÚ5ck[/˚Ó4˜!˜$È„˜Ï˚˜—HV[BEWªÃÃπ¥—‹æcKÚ¢˚⁄5XZ1.Q¡‚◊«¿‡ÂƒV9˚*†v¯üwò¯r¯˚L˜†˜E˜ì˚ ˚˚M˚˜M˚˜B˚ì˚K˚†˜˜˜Y˜˚Y‚x ﬂŒ˜‡Ãﬁ…}÷Ìÿ˜úœˆ÷˘Ç˜˚˜e˚?˜=˚g˚g˚?˚=˚e˚e˜?˚=˜g˜g˜?˜=˜e@˚B˚˚!˚>˚>˚˜!˜B˜C˜˜!˜>˜>˜˚!˚C EGM{dkM6M—Ï√À‚»≤mM†ŒÙuMø"˚3.˚˚Ë)˜È ¬ıß-x⁄˜…⁄˜E⁄±‰2Ú˜ß‡AÂÚ¯ô˜q˜1Ë˚@VpOdàçï˜?«ÊÒãÏÀ≥fCò‡Ü«~´i≠e≤Q¢Rã˚5ã*˚#ã˚ã˚v·˚˜7ãÍ˜ÏÒ˜1Ü0RJ94OÀÁÁƒ»‡„√P-˜∫†v˘awõ˙"˙2˘a ˚¸€â˚4¯€"˚6¸€â˚¯€#˜O˝a˜:¯Áéå˜7¸ËÒúãﬁ˜êŸ˜r›‘Ï˜ÿÎMÎ¯˘˜l‡gª-±Õ≠©ª–ˆ:”˚˚Œ˝a˜ Ù˜%Î·˜¯˚˜À?Ye(˚C˜r˜CÔºgCÙ≠˚Õ7U\*˚c˜ê˜R˜≈b;¯x…ËÃJ‘˜∏”Ò»˜'‘◊ﬁ¯:Ãﬂ˘ˆ¯>˜C˚*˜˚V˚e˚:˚:˚d˚k˜:˚:˜l˜˜Œ˜ I@H8d/˚B˚˜˜C˜K˜˜˜A˜3˜˚˚$ F˚Cyäöö§ßÈ»˜cGwMlƒj†Wã˚$˚˚,5ÕAÿ∂¨òΩªçaè†v±Æ¿¢¨¥“∆±›Ëˇ˚ìy*>%A[j≥ƒÏ’Ì‘π≤`Y˜K†v˘aw‘Ë.Ê¯äÈ/Á‰˘å˘a˚˚_¸Òâ˚a¯Ò˚˝aË¯<‘«â∆ã«Ëç˜_¸ÔÎ˜]¯‰çËä˚	ä∫;ããã¸Zu°¯üö˜)õôü˜°ñ¸}ö◊
„
_˜™˘
endstream
endobj
33 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 47/slash 58/colon 65/A/B/C/D/E 71/G 73/I/J 76/L/M/N/O 82/R/S/T/U/V 89/Y 97/a 99/c/d/e/f/g/h/i 108/l 110/n/o/p 114/r/s/t/u]/Type/Encoding>>
endobj
35 0 obj
<</Ascent 750/CapHeight 717/Descent -205/Flags 262176/FontBBox[-170 -227 1001 963]/FontFile3 34 0 R/FontName/ITLCLN+Helvetica-Bold/ItalicAngle 0/StemH 0/StemV 140/Type/FontDescriptor/XHeight 737>>
endobj
34 0 obj
<</Length 2993/Length1 2993/Subtype/Type1C>>stream
  ITLCLN+Helvetica-Bold   @¯ ¯¯¯¯˚>˚w˙}˙W
 ãã
 ãã      Q≤  ä Äçï002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki BoldHelsinki  $  0 # + & $ 5 * 7  " 4 6 . 3 : % / - B T F  Q P S U J D V O I M ( H E  G &   T Œ2Ñ¶ΩÁI÷L±›$SnÓX∫Ω(o¥f≠ı<Sπ	2	î	±	È˜x˜¯ä˜∑˘F˘r˜˙˜m˚˜6˚v˚u˚˚4˚o˚n˜	˚3˜x˜t˜˜4˜m˚*å˚0A,˚˚AÍ˜0˜/÷Î˜˜÷+˚/”ã˜˜U˜˜0˜◊˜$˜Æ˜#˚˜)Ù˘0˜m‡m∫:±¯ Æ§¥Œ˜5”˚˚˝a˜≈ﬁ»ïû≠Ùœ±¥—€¯˚:˜¡XdmG˚C˜0˜?◊ÆtWÙú˚∫KafC˚M˜U˜Sœ≥iQ-y˜¯˙w°˜˜A˜*¯w˜d¯ë˚*¸ë?snNKs±Ú¶˚l˚OÃD˜A˜'◊ÿ˜)úã˜˜O˜˜+˜◊˜'˘ ˜¸!˜O˜˜˚˜+¯˜¸¢˝a”x˜¯É˜∑˘˘?˜â˚)*n_f6˚HÁ˜,˜4ÕÊ˜
ﬁµi1ß˜(˜-~˚˚A˚]˚˚'˚|˚|˜˚$˜^˜;ˆÊ˜A∞d†v¯„˜˜z˜+¯Ë¯„˜¸⁄˚˜l¸„˜+¯„¸†v˘awÀ˜*˜j˘a˚*˝aú†v˘awû˘˘˘a˚/˚0¸≥âä˚.¯¥˚4˜Ü˝a˜#˚—ã˜%˜r˜%Á˜*˜Ü¯˜%˚*˚%˜*¸˜%˚*˚%”†v˜'˜¯Qwü˘;˘O˚ë˘a˚A˚ë˝a˜1Ω˜'˜ùπ˚'3˜§˚LÁ˜∞çúw˜˜I˜$˜'˜6˜≤˜"˚˜˜•˜#˚˜%’˘	˜lÚS√˚¨ˆ˚C∑Sôv†ã¥¿º¨◊Ê∫hBï˜#˜$Ñ ‚˚;˚A&8˚"˚*ıo˜nŸÿyÓt™vã^NYl&,Z∞ŸÉ˚"çCôd±aøSÂk˜ã˜@ã˜Áã˜$”x˜¯ˆw”¯÷˘˜é¯g˚,¸m/[^*;[¬Â¯e˚-¸p˚7ı*˜F˜TÒË˜D˜K†v˘aw–˜ ¯4˜˘ê˘a˚l˚¸…à˚¯…˚o˝a˜ ¯Ïç˜¸Ï˜(˜¯Ïç¸Ï”†v˜Æ˜˜T˜◊˜(˜∏˜(˘9ûsîÑù¿˜HÄ©:Ø’©Øƒﬂ˜3⁄˚˚ˇå˝a˜'˜Æ˜/Óöy˚
çåFéoòZè¯ÜIgn:˚C˜T˜OŒ±hMú†v˘awö˘˘˘a˚=˚!˚À˚*˜À˚D˜å¸S˚¢˜+˜°”ã˜¯i˜◊˜'˜»˜,˘?¯˜n'˜˚S˚–˝a˜À˜J˜˜%˜{˚,˚(M0'˚&¯i˜$˜¿@˚/”†v˘aw–˜ ˜ƒ˜ ˘!˘a˚ ¸àâ˚±¯à˚1˝a˜ ¯îç˜∏¸îdã˜¯ﬂw◊¯é¯⁄˜˚¯¯ﬂ˚*˝a-}ÔJv˜z‹˜˜®˜˜Q˜|¯°†uíÇ£ø˜¥Î;≈˚˚0FU˚Ä˜Ωèß£¿ ®x`t|}iÜ˚x${XRã*¸.ÀMÎ”≤ù∆…|åqçÅîp¸z˜SRS[K`q§≤ª°û“ò–òàä©ú-}ı˜ı©˜#˚˜˚˜˜a˜ ‘¯ö˜9˜d˚·?ãÍ©´ù¿«®uZë˜˜Ñ;≈˚-˚;D ˚X˜› ã3ggxVÃ=h¢¬à‰˚#˚çÎE˜0˜#Ê–˜-}˜˜Ê˜˜¢˜#˚#˜ ˜p˜#Ù¯¢˜x§˜P2Ù˚5˚4.%˚D˚IÁ&˜9˜⁄¬˜Ø˚#cyny\ÏAdµ‰ÑÙ˜pÊ˚m⁄ò´¨  Øf@ï¸d˚Nv˜U˜˜Ÿ˜{w…˜˚˜!˜{˜#Í¯’˜§˜82˜˚AcsF^â˙ÿ˚˝vÊ˜!˜¶çå≠Rπr–ã˜·˜˜D˚#Ç)^KEÍ?\∆È˜¥∆Ÿ÷∑O$d}˜	˜Ÿ˜
≠˜#˜ï˜#¯’˜û˜?!˜˚9˚:!˚˚?˚AÛ ˜<˜;Û˜ ˜@˚# _S76_√ˆÙ∏ƒﬂﬁ∏R"˚ô†v¯(˜"|wÀ˜˚˜ ¯¯%˜"éÜãÅJgp<_âÊ˚¸ßË˜ ˜®ﬂ∑∑ﬂñîäâü˚—Öı˜ﬂÔ›˜ ˜»àıâ|Ñä^Ñë±˜≥·Ô5˜%˚ ˚%C'”˚’7≥kÚùûôåç´¸†v¯ßwﬁ˜–˜ ˜e¯Ê˜˚ ˚˜ ¸Ê¯ß˚ ¸ß-}˜˜€˜
≠˜$˜`˜!¯ü˜V˚!KjnSHg¡˜ı≥≈’∫©pPò˜!˜É+‘˚˚71$˚O˚?Â(˜/˜Âÿ˜ùd}˜
8v¯ßwÕ˜ ˜[˜˚˜Ù¯≥¯ß¯˚˚«B`\IOm¨Ã˜›˚ ˚Ò˚ÕC˜÷æß»ØÙç@d†v¯?˜|wÃ˜˚˜ ˜]˜Ù¯¥¯˜Dœ˚C_rH`âÙÿ˚¸ßÏ˜ ˜ƒÿµπ—«®iE˚◊d†v¯@˜˜>wÃ˜˚˜ ˜]˜Ù¯µ¯˜C—˚CVnUoà˜ë˚˝aÏ˜ ˜≈ﬂ≥≤’∆ßjC˚◊¸†v˘aw–˜ ˜e˘a˚ ˝a˜x˜4v˜û˜˜u˜¯◊˜x˘[¯˚Ω˚˜9¯˚ oQY*˚AÁ˜0˜4ŸÏ˜◊∆_B°˜(˜)x˚Ê˚C˚i˚˚(˚z˚v˜˚+˜YÌÃ´Ÿ»xô0d˚mı˜ ˜
˜…˜|w≥˜#˜z˜˚˜⁄¯º®¯ä˚<â¸ÀmX©D˚4!˚<˚?‚#˜!–¥£ƒ´éáL4hh>Ktò¥Å˚,#óﬁS˜'˜èí˜.Á˚˜Ñ*eR:G`«ÈÍ∂«Œ◊∑J1d}˜;v¯<˜˜?w≠˜$˜|˜˚˜z¯∏˘a¸˚˚ìâ ^d†D˚5˚ ˚;˚@‰˚˜œæ¶¡ÆçzH˙é˜ò&^Q=E^ ÏÛµ∆÷⁄µR ¸çv˘àwj˜Î˜ ˘u˚	˚v˝à˜˚—†v¯EÌ‹˜·˜ ˜—¯EÌ0†øëìµ≤˜çhÄãq#XZ%_?)◊¸E˜ ¯Ewü¯ßö˜,óíüòã˜£ó¸|ãı
˜ å
_˜™˘
endstream
endobj
76 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
77 0 obj
<</OP false/OPM 0/op false>>
endobj
84 0 obj
<</A 85 0 R/Border[0 0 0]/Rect[243.612 9.0 285.357 16.0]/Subtype/Link/Type/Annot>>
endobj
85 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
70 0 obj
[86 0 R]
endobj
71 0 obj
<</Length 13797>>stream
1 g
/GS0 gs
0 783 0 0 re
f
0 0 0 0 k
/GS1 gs
50.5 36.5269 493 696.6661 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.01801 Tc 0.01801 Tw 10.5 0 0 10.5 61 726.0132 Tm
(Careful consideration must be given to the potential for)Tj
-0.02361 Tc -1 -1.23095 Td
(an)Tj
-0.024 Tc 0.024 Tw 1.14663 -0.00001 Td
[(antipsychotic to prolong the QT)70 (c interval, since critical-)]TJ
-0.02299 Tc 0.02299 Tw -1.14663 -1.23095 Td
(ly ill patients may have prolongation prior to antipsychotic)Tj
-0.00011 Tc 0 -1.23096 TD
(i)Tj
0 Tc 0.08099 Tw (nitiation from factors such as other medications, elec-)Tj
0.004 Tw T*
[(trolyte abnor)-25 (malities, and concurrent disease states.)]TJ
ET
BT
/T1_1 1 Tf
0.002 Tc 0 Tw 6 0 0 6 267.5877 677.6132 Tm
(24)Tj
ET
BT
/T1_0 1 Tf
0 Tc 10.5 0 0 10.5 276.2558 674.313 Tm
(In)Tj
-0.01601 Tc 0.01601 Tw -21.50055 -1.23095 Td
(2007, the Food and Drug Administration \(FDA\) strength-)Tj
0 Tc 0.01801 Tw 0 -1.23095 TD
[(ened war)-25 (nings regarding QT)70 (c interval prolongation and)]TJ
-0.005 Tc 0.005 Tw T*
(TdP with use of intravenous haloperidol, recommending)Tj
-0.013 Tc 0.013 Tw T*
(continuous electrocardiograph \(ECG\) monitoring with its)Tj
-0.015 Tc 0 Tw T*
(use.)Tj
ET
BT
/T1_1 1 Tf
-0.013 Tc 6 0 0 6 66.5066 612.9881 Tm
(25)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 0.015 Tw 10.5 0 0 10.5 74.9567 609.688 Tm
[(This war)-25 (ning did not apply to oral haloperidol, as it)]TJ
-0.01801 Tc 0.01801 Tw -2.32921 -1.23095 Td
[(has similar potential for prolonging the QT)70 (c interval com-)]TJ
0 Tc 0.134 Tw T*
(pared with risperidone and olanzapine.)Tj
ET
BT
/T1_1 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 219.1058 587.1381 Tm
(26,27)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.134 Tw 10.5 0 0 10.5 236.6402 583.8381 Tm
(Among the)Tj
-0.019 Tc 0.019 Tw -17.72764 -1.23095 Td
(SGAs, ziprasidone has demonstrated the greatest potential)Tj
0 Tc 0.157 Tw T*
[(to prolong the QT)70 (c interval.)]TJ
ET
BT
/T1_1 1 Tf
0.002 Tc 0 Tw 6 0 0 6 173.8619 561.2881 Tm
(27)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.157 Tw 10.5 0 0 10.5 184.1358 557.9881 Tm
(The FDA also recently)Tj
-0.019 Tc 0.019 Tw -12.72722 -1.23095 Td
[(strengthened the war)-25 (ning of QT)70 (c interval prolongation as-)]TJ
-0.02499 Tc 0.011 Tw T*
(sociated with quetiapine use.)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 164.5342 535.438 Tm
(28)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.011 Tw 10.5 0 0 10.5 172.7154 532.1381 Tm
[(Conversely)65 (, aripiprazole has)]TJ
0 Tc -11.63956 -1.23095 Td
[(been shown to have minimal ef)20 (fect on the QT)70 (c interval,)]TJ
0.00101 Tw T*
[(with no reported cases of TdP)110 (.)]TJ
ET
BT
/T1_1 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 177.672 509.5881 Tm
[(2)-1 (9)-24 (-38)]TJ
ET
BT
/T1_0 1 Tf
0 Tc 0.00101 Tw 10.5 0 0 10.5 194.4518 506.2881 Tm
[(However)40 (, we report a)]TJ
-0.01801 Tc 0.01801 Tw -13.7097 -1.23095 Td
(case of nonfatal TdP associated with the administration of)Tj
-0.02499 Tc 0.013 Tw T*
(aripiprazole in a patient with minimal risk factors. )Tj
ET
BT
/T1_2 1 Tf
0.011 Tw 10.5 0 0 10.5 50.5 452.5131 Tm
(Case Report)Tj
ET
BT
/T1_0 1 Tf
-0.00011 Tc 0 Tw 10.5 0 0 10.5 61 431.5881 Tm
(A)Tj
0 Tc 0.97201 0 Td
(42-year)Tj
-0.015 Tc 3.03335 0.00001 Td
[(-)-90 (old white male with schizophrenia, diabetes)]TJ
-0.026 Tc 0.011 Tw -5.00536 -1.23096 Td
(mellitus, hypertension, and previous stroke presented to the)Tj
-0.039 Tc 0.024 Tw T*
[(emer)20 (gency department following 2 days of fever)40 (, chills, diar-)]TJ
T*
(rhea, and altered mental status. He was admitted to the medi-)Tj
-0.03999 Tc 0.008 Tw T*
(cal ICU for the treatment of sepsis. His ICU course was com-)Tj
-0.019 Tc 0.004 Tw T*
(plicated by the development of severe sepsis, renal failure,)Tj
-0.015 Tc 0.12601 Tw T*
[(adrenal insuf)20 (ficiency)65 (, and acute respiratory distress syn-)]TJ
-0.03999 Tc 0 Tw T*
(drome.)Tj
-0.02499 Tc 0.01401 Tw 1 -1.23095 Td
(One we)Tj
-0.03999 Tc [0.4 (ek into the hospital course, the patient was exhibit)]TJ
0 Tc 21.00056 0.00001 Td
(-)Tj
-0.02499 Tc 0.00999 Tw -22.00056 -1.23096 Td
(ing symptoms thought to be related to hypoactive delirium,)Tj
-0.02 Tc 0.005 Tw T*
(schizophrenia, or both. The dose of quetiapine used before)Tj
-0.02299 Tc 0.008 Tw T*
(admission \(400 mg by mouth at bedtime\) was restarted but)Tj
-0.035 Tc 0.02 Tw T*
[(discontinued after 1 dose when the QT)70 (c interval was discov-)]TJ
-0.01601 Tc 0.00101 Tw T*
(ered to be 644 milliseconds. The only prior ECG obtained)Tj
-0.037 Tc 0.022 Tw T*
[(was upon arrival at the emer)21.8 (gency department 7 days earlier)]TJ
0 Tc 22.08325 0.00002 Td
(,)Tj
-0.03999 Tc 0.02299 Tw -22.08325 -1.23098 Td
[(which revealed an interval of 528 milliseconds. T)70 (wenty-three)]TJ
-0.026 Tc 0.011 Tw T*
(days after quetiapine administration and at resolution of the)Tj
-0.015 Tc 0 Tw 0 -1.23096 TD
(patient\325)Tj
-0.01511 Tc 2.87878 0.00001 Td
(s)Tj
-0.015 Tc 0.019 Tw 0.62794 0 Td
[(acute illness, a new baseline QT)70 (c interval of 414)]TJ
0.04201 Tw -3.50672 -1.23095 Td
(milliseconds was obtained. Given the significant changes)Tj
0 Tw 0 -1.23095 TD
(with quetiapine, aripiprazole was initiated because of data)Tj
-0.033 Tc 0.01801 Tw T*
[(supporting its minimal ef)20 (fect on the QT)70 (c interval. Following)]TJ
-0.01711 Tc T*
(5)Tj
-0.017 Tc 0.002 Tw 0.71787 0 Td
[(days of aripiprazole 2.5 mg orally once daily)65 (, the patient)]TJ
-0.028 Tc 0.013 Tw -0.71787 -1.23095 Td
[(had a cardiac arrest due to TdP)110 (, identified by an ECG. Min-)]TJ
-0.015 Tc 0 Tw T*
[(utes prior to the event, an ECG recorded a QT)70 (c interval of)]TJ
-0.02901 Tc 0.01401 Tw T*
(624 milliseconds. The patient received cardiopulmonary re)Tj
0 Tc 22.00041 0.00001 Td
(-)Tj
-0.03999 Tc 0.002 Tw -22.0004 -1.231 Td
(suscitation for 30 seconds, 1 shock of 200 Joules, and magne)Tj
0 Tc 22.00056 0.00001 Td
(-)Tj
-0.015 Tc 0.168 Tw -22.0006 -1.231 Td
[(sium sulfate 4 g given intravenous push. Nor)-21.2 (mal sinus)]TJ
-0.03999 Tc 0.013 Tw 0.00002 -1.23099 Td
(rhythm was restored and aripiprazole was discontinued. )Tj
0 Tc 0.05299 Tw 1 -1.2381 Td
(The only additional risk factor present at the time of)Tj
-0.022 Tc 0.022 Tw -1 -1.2381 Td
[(TdP was concomitant intravenous famotidine 20 mg daily)65 (.)]TJ
0 Tc 0.27901 Tw 0 -1.2381 TD
(Relevant laboratory findings included potassium 3.8)Tj
0.00101 Tw 24.61905 64.99049 Td
(mEq/L, magnesium 1.5 mg/dL, and calcium 8.8 mg/dL.)Tj
-0.008 Tc 0.008 Tw 0 -1.23809 TD
[(Additionally)65 (, a cardiac catheterization conducted the fol-)]TJ
-0.01801 Tc 0.017 Tw 0 -1.2381 TD
(lowing day did not reveal any significant disease. Follow-)Tj
-0.01579 Tc T*
(up)Tj
-0.01601 Tc 0.01601 Tw 1.21832 -0.00001 Td
[(QT)70 (c measurements 1, 5, and 14 days after aripiprazole)]TJ
-0.008 Tc 0.008 Tw -1.21832 -1.23809 Td
(discontinuation were 537, 472, and 450 milliseconds, re-)Tj
-0.01601 Tc 0.01601 Tw T*
[(spectively)65 (. There were no ECG data prior to this hospital-)]TJ
-0.013 Tc 0.013 Tw T*
(ization for analysis and no documentation of a congenital)Tj
-0.01401 Tc 0.01401 Tw 0 -1.23809 TD
(long QT syndrome. After evaluation of the case using the)Tj
0 Tc 0.004 Tw 0 -1.2381 TD
(Naranjo probability scale,)Tj
ET
BT
/T1_1 1 Tf
0.002 Tc 0 Tw 6 0 0 6 417.8164 625.3132 Tm
(39)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.004 Tw 10.5 0 0 10.5 426.4782 622.0132 Tm
[(it was deter)-25 (mined that there)]TJ
-0.01601 Tc 0.01601 Tw -11.1884 -1.2381 Td
(was a probable relationship between the onset of TdP and)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(aripiprazole therapy in this patient. )Tj
ET
BT
/T1_2 1 Tf
0 Tw 10.5 0 0 10.5 309 568.2131 Tm
(Discussion )Tj
ET
BT
/T1_0 1 Tf
-0.009 Tc 0.009 Tw 10.5 0 0 10.5 319.5 547.4132 Tm
(Aripiprazole is an antipsychotic with partial dopamine)Tj
-0.015 Tc 0.015 Tw -1 -1.21906 Td
[(agonist properties that may have positive ef)20 (fects on atten-)]TJ
-0.02499 Tc 0.022 Tw 0 -1.21904 TD
(tion, concentration, and sleep-wake cycle reversal in deliri-)Tj
-0.015 Tc 0 Tw 0 -1.21905 TD
(um.)Tj
ET
BT
/T1_1 1 Tf
0 Tc 6 0 0 6 324.582 512.3132 Tm
(7)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 0.015 Tw 10.5 0 0 10.5 330.1193 509.0131 Tm
(It has been proposed that these properties may make)Tj
-0.01601 Tc 0.01601 Tw -2.01136 -1.21905 Td
(aripiprazole an ideal agent in hypoactive delirium, a com)Tj
0 Tc 22.00047 0.00001 Td
(-)Tj
0.08501 Tw -22.00047 -1.21906 Td
[(monly underdiagnosed for)-25 (m of ICU delirium.)]TJ
ET
BT
/T1_1 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 505.5812 486.7132 Tm
(7,40)Tj
ET
BT
/T1_0 1 Tf
0 Tc 10.5 0 0 10.5 519.5979 483.4131 Tm
(Other)Tj
-0.01401 Tc 0.013 Tw -20.05694 -1.21905 Td
(properties of aripiprazole include minimal antagonism on)Tj
-0.007 Tc 0.007 Tw T*
(muscarinic, histaminic, and )Tj
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 10.5 0 0 10.5 425.1941 457.8131 Tm
(a)Tj
ET
BT
/T1_1 1 Tf
6 0 0 6 431.7424 455.8331 Tm
(1)Tj
ET
BT
/T1_0 1 Tf
-0.007 Tc 0.007 Tw 10.5 0 0 10.5 437.3241 457.8131 Tm
[(adrener)20 (gic receptors. Ari-)]TJ
-0.02499 Tc 0.015 Tw -12.22134 -1.21905 Td
(piprazole also has lower incidences of drug-induced move)Tj
0 Tc 22.00057 0 Td
(-)Tj
0.075 Tw -22.00057 -1.21905 Td
(ment disorders and neuroleptic malignant syndrome as)Tj
-0.01401 Tc 0.01401 Tw T*
(compared with haloperidol.)Tj
ET
BT
/T1_1 1 Tf
-0.01151 Tc 0 Tw 6 0 0 6 421.3359 422.7131 Tm
(41)Tj
ET
BT
/T1_0 1 Tf
-0.01401 Tc 0.01401 Tw 10.5 0 0 10.5 429.7984 419.4131 Tm
[(Additionally)65 (, aripiprazole is)]TJ
-0.006 Tc 0.006 Tw -11.50461 -1.21905 Td
(available as an intramuscular injection, an orally disinte)Tj
0 Tc 22.00048 0 Td
(-)Tj
-0.015 Tc 0.015 Tw -22.00048 -1.21905 Td
(grating tablet, a tablet, and a liquid, allowing for adminis-)Tj
0 Tc 0.03 Tw T*
(tration when barriers to drug delivery may be present.)Tj
ET
BT
/T1_1 1 Tf
0.002 Tc 0 Tw 6 0 0 6 537.4996 384.3131 Tm
(42)Tj
ET
BT
/T1_0 1 Tf
-0.017 Tc 0.01601 Tw 10.5 0 0 10.5 309 368.2131 Tm
(Despite these properties, there is a lack of data supporting)Tj
0 Tc 0 Tw T*
(ef)Tj
0.088 Tw 0.75659 0 Td
(ficacy and safety of aripiprazole for the treatment of)Tj
-0.02499 Tc 0 Tw -0.75659 -1.21905 Td
(delirium. )Tj
-0.01401 Tc 0.01401 Tw 1 -1.2381 Td
[(No data regarding the ef)20 (fect of aripiprazole on the QT)70 (c)]TJ
-0.017 Tc 0.017 Tw -1 -1.23809 Td
[(interval in ICU populations exist. A)73.9 (vailable cardiac safety)]TJ
-0.004 Tc 0.004 Tw 0 -1.2381 TD
(data may be extrapolated from psychiatric clinical trials,)Tj
-0.021 Tc 0.021 Tw T*
(non-ICU delirium trials, and overdose reports, which have)Tj
-0.02499 Tc 0.01401 Tw 0 -1.23809 TD
[(shown aripiprazole to have a minimal ef)20 (fect on the QT)70 (c in-)]TJ
0 Tc 0.009 Tw 0 -1.2381 TD
(terval, with no reported cases of TdP)Tj
-0.00011 Tc 14.68909 0.00001 Td
(.)Tj
0 Tc 0.50906 0 Td
(In fact, some data)Tj
-0.02499 Tc 0.022 Tw -15.19816 -1.2381 Td
[(suggest that QT)70 (c interval shortening may occur)55 (. In a recent)]TJ
-0.01801 Tc 0 Tw 0 -1.23809 TD
(letter)Tj
-0.0179 Tc 1.90694 0.00001 Td
(,)Tj
-0.01801 Tc 0.01801 Tw 0.48198 0 Td
[(Muzyk et al. retrospectively evaluated the ef)17.3 (fects of)]TJ
-0.02499 Tc 0.024 Tw -2.38892 -1.2381 Td
[(intramuscular aripiprazole administration on the QT)70 (c inter-)]TJ
-0.004 Tc 0.004 Tw 0 -1.2381 TD
(val in medically ill patients.)Tj
ET
BT
/T1_1 1 Tf
-0.002 Tc 0 Tw 6 0 0 6 424.8551 215.9131 Tm
(43)Tj
ET
BT
/T1_0 1 Tf
-0.004 Tc 0.004 Tw 10.5 0 0 10.5 433.4329 212.6131 Tm
(Intramuscular aripiprazole)Tj
-0.009 Tc 0.009 Tw -11.85075 -1.23809 Td
(\(mean dose 9.64 )Tj
0 Tc [0.3 (\261)]TJ
-0.009 Tc 7.5046 0.00002 Td
(1.96 mg\) was administered to 14 men)Tj
-0.02499 Tc 0.019 Tw -7.5046 -1.23811 Td
[(and 7 women \(mean age 61.1 \261)-228 (14.5 years\), 86% of whom)]TJ
0 Tc 0.063 Tw T*
[(were on concomitant medications known to cause QT)70 (c)]TJ
-0.02299 Tc 0.02299 Tw 0 -1.23809 TD
[(prolongation. The reported change of the QT)70 (c interval was)]TJ
0 Tc 0 Tw 0 -1.2381 TD
(2.1 )Tj
0.02699 Tw 1.52693 0.00001 Td
[(\261)-262 (7.3 milliseconds from a mean baseline of 479.8 \261)]TJ
-0.011 Tc 0.011 Tw -1.52693 -1.2381 Td
[(46.2 milliseconds \(p = 0.39\). T)70 (en of the 21 patients had a)]TJ
-0.02499 Tc 0.015 Tw 0 -1.23809 TD
(decrease in QT)Tj
-0.0251 Tc 5.66121 0.00001 Td
(c)Tj
-0.02499 Tc 0.65869 0 Td
(interval \(range 10)Tj
0 Tc 6.76195 0.00001 Td
(-)Tj
-0.02499 Tc [0.3 (32 milliseconds\). How)]TJ
0 Tc 8.91872 0.00002 Td
(-)Tj
-0.024 Tc 0.024 Tw -22.00057 -1.23812 Td
[(ever)40 (, 6 patients had an increase of greater than 30 millisec-)]TJ
-0.02499 Tc 0.019 Tw 0 -1.2381 TD
[(onds from baseline \(range 30)-75 (-)-25 (82 milliseconds\). Discussion)]TJ
-0.02299 Tc 0.022 Tw 0 -1.23809 TD
[(regarding patients with lar)5.7 (ge increases in QT)]TJ
-0.02251 Tc 17.02749 0.00002 Td
(c)Tj
-0.02299 Tc 0.67136 0 Td
(interval was)Tj
-0.024 Tc 0.024 Tw -17.69884 -1.23811 Td
[(not provided, making it dif)20 (ficult to estimate the probability)]TJ
-0.021 Tc 0.021 Tw 0 -1.2381 TD
(that aripiprazole was responsible. Limitations of this study)Tj
-0.01199 Tc 0.01199 Tw 0 -1.23809 TD
(consist of the small number of patients, and while the au-)Tj
ET
0 0 0 0 k
50.5 14 378.5 14.524 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.02299 Tc 0 Tw 10 0 0 10 50.5 21.6856 Tm
[(e1)57 (1)]TJ
ET
BT
/T1_4 1 Tf
0 Tc 5 0 0 5 73.1366 23.1856 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 86.3177 21.6856 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 219.4427 23.1856 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 232.6237 21.6856 Tm
[(2013 February)55 (, V)110 (olume 47)]TJ
ET
0 0 0 0 k
463 17.694 80.5 10.806 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tw 10 0 0 10 488.4582 21.6616 Tm
(theannals.com)Tj
ET
0 0 0 0 k
50.5 740.1929 234 10 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
-0.0251 Tc 8 0 0 8 50.5 744.7228 Tm
(S)Tj
-0.02499 Tc 0.013 Tw 0.76835 0 Td
(Nelson, JG Leung)Tj
ET
BT
0 g
/GS2 gs
/T1_7 1 Tf
0 Tc 0 Tw 5 0 0 5 284.35733 11 Tm
( at UNIV CALGARY LIBRARY on May 25, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
52 0 obj
<</BaseFont/YGSLBL+Symbol/Encoding 49 0 R/FirstChar 32/FontDescriptor 51 0 R/LastChar 97/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 631]>>
endobj
49 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 97/alpha]/Type/Encoding>>
endobj
51 0 obj
<</Ascent 921/CapHeight 671/Descent -223/Flags 4/FontBBox[-180 -292 1090 1005]/FontFile3 50 0 R/FontName/YGSLBL+Symbol/ItalicAngle 0/StemH 0/StemV 41/Type/FontDescriptor/XHeight 684>>
endobj
50 0 obj
<</Length 446/Length1 446/Subtype/Type1C>>stream
  YGSLBL+Symbol   F¯ ¯¯¯¯)¡˚H˚∏˙÷˙Å
 ãã
 ãã   ˙   ˆ   ˇ™  ü Ñãalpha002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Simpele is a trademark of Stream Technologies Inc.Simpele     á ö¸$xyÆk”¯'≥}w≥ÒX¯ˇ˜xUÑypljp¥‘{˜˜œ3L˚Dà¯˜tP *VWt\_`_xI.˚*Ÿ,˜≥¿õ°≠´†û•®≈x&ØßdØ™Æ∫∫ç˚h˜%m:¯=n\[]qtôßus´|œ‹˜∏ÊÃ∂πoeûönûNèms£¯Üç˜?ò˜Åã˚véØ
¥
_˜é˘
endstream
endobj
72 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
73 0 obj
<</OP false/OPM 0/op false>>
endobj
86 0 obj
<</A 87 0 R/Border[0 0 0]/Rect[243.612 9.0 285.357 16.0]/Subtype/Link/Type/Annot>>
endobj
87 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
65 0 obj
[88 0 R]
endobj
66 0 obj
<</Length 11656>>stream
1 g
/GS0 gs
0 783 0 0 re
f
0 0 0 0 k
/GS1 gs
51.528 32.7739 492 498.167 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
27.357 0 0 27.357 50.1452 510.7603 Tm
(H)Tj
ET
BT
/T1_1 1 Tf
0.283 Tw 10.5 0 0 10.5 69.778 523.7603 Tm
(aloperidol, a first-generation an-)Tj
-0.02 Tc 0.02 Tw 0 -1.2381 TD
(tipsychotic, has been considered the)Tj
-0.01401 Tc 0.01401 Tw -1.7381 -1.2381 Td
(gold standard for the treatment of inten-)Tj
-0.006 Tc 0.006 Tw 0 -1.23809 TD
(sive care unit \(ICU\) delirium.)Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 6 0 0 6 174.3467 488.0604 Tm
(1)Tj
ET
BT
/T1_1 1 Tf
-0.006 Tc 0.006 Tw 10.5 0 0 10.5 179.9351 484.7603 Tm
(In an at-)Tj
0 Tc 0.088 Tw -12.22925 -1.2381 Td
[(tempt to use ef)22.3 (fective, and potentially)]TJ
-0.02299 Tc 0.022 Tw T*
(safer agents, clinicians have increasingly)Tj
0 Tc 0.71001 Tw T*
[(ordered second-generation antipsy)3 (-)]TJ
-0.02499 Tc 0.013 Tw 0 -1.2381 TD
(chotics \(SGAs\) for managing ICU deliri)Tj
0 Tc 15.19104 0 Td
(-)Tj
-0.01601 Tc 0.01601 Tw -15.19104 -1.2381 Td
[(um. However)40 (, only olanzapine, quetiap-)]TJ
0 Tc 0.017 Tw 0 -1.23809 TD
(ine, and ziprasidone have been studied)Tj
0.00999 Tw T*
[(for ICU delirium in a prospective, ran)4.9 (-)]TJ
0.32899 Tw 0 -1.2381 TD
[(domized controlled manner)55 (.)]TJ
ET
BT
/T1_2 1 Tf
0 Tw 6 0 0 6 175.946 384.0604 Tm
[(2)-25.9 (-)-75.7 (4)]TJ
ET
BT
/T1_1 1 Tf
10.5 0 0 10.5 190.626 380.7603 Tm
(Other)Tj
-0.02499 Tc 0.011 Tw -13.24743 -1.23809 Td
(SGAs with literature supporting their use)Tj
0 Tc 0.202 Tw 0 -1.23809 TD
(for delirium include aripiprazole and)Tj
-0.02299 Tc 0.02299 Tw 0 -1.2381 TD
[(risperidone. However)40 (, these data involve)]TJ
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(only non-ICU populations.)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 158.0873 332.0604 Tm
[(5)-25 (-17)]TJ
ET
BT
/T1_1 1 Tf
0 Tc 10.5 0 0 10.5 62.028 315.7603 Tm
(Antips)Tj
-0.015 Tc 0.13499 Tw 2.6665 0.00001 Td
(ychotics pri)Tj
0 Tc 4.64745 0 Td
(marily exert their)Tj
0.13901 Tw -8.31395 -1.2381 Td
(action through dopamine antagonism.)Tj
0.061 Tw T*
[(Examples of adverse ef)20 (fects related to)]TJ
0.16701 Tw 0 -1.2381 TD
(this mechanism include drug-induced)Tj
-0.02499 Tc 0.017 Tw 0 -1.23809 TD
(movement disorders and neuroleptic ma-)Tj
0 Tc 0.13901 Tw 0 -1.2381 TD
(lignant syndrome. These types of ad-)Tj
-0.00999 Tc 0.00999 Tw T*
(verse events are less likely to be caused)Tj
-0.007 Tc 0.007 Tw 0 -1.23809 TD
(by SGAs than by haloperidol.)Tj
ET
BT
/T1_2 1 Tf
-0.005 Tc 0 Tw 6 0 0 6 174.9286 228.0604 Tm
(18)Tj
ET
BT
/T1_1 1 Tf
-0.007 Tc 10.5 0 0 10.5 183.4727 224.7603 Tm
(Proper)Tj
0 Tc 2.62482 0.00001 Td
(-)Tj
-0.02499 Tc 0.015 Tw -15.19098 -1.2381 Td
(ties of SGAs that may account for a low)Tj
0 Tc 15.19103 0.00001 Td
(-)Tj
0.09399 Tw -15.19103 -1.2381 Td
[(er adverse ef)20 (fect burden include sero-)]TJ
0.13699 Tw T*
(tonin 5)Tj
0 Tw 2.96713 0.00001 Td
(-HT)Tj
ET
BT
/T1_2 1 Tf
0.002 Tc 6 0 0 6 100.1709 183.7802 Tm
(2A)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0.13699 Tw 10.5 0 0 10.5 111.5614 185.7603 Tm
(antagonism, faster dissociation from the)Tj
-0.015 Tc 0.015 Tw -5.71747 -1.2381 Td
(dopamine D)Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 6 0 0 6 101.7506 170.7802 Tm
(2)Tj
ET
BT
/T1_1 1 Tf
-0.015 Tc 0.015 Tw 10.5 0 0 10.5 107.2875 172.7603 Tm
[(receptor)40 (, and/or lower D)]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 6 0 0 6 206.819 170.7802 Tm
(2)Tj
ET
BT
/T1_1 1 Tf
-0.015 Tc 0.015 Tw 10.5 0 0 10.5 212.3558 172.7603 Tm
(receptor occupan-)Tj
-0.02499 Tc 0 Tw -15.31693 -1.2381 Td
[(cy)65 (.)]TJ
ET
BT
/T1_2 1 Tf
-0.024 Tc 6 0 0 6 62.5914 163.0604 Tm
(19,20)Tj
ET
BT
/T1_1 1 Tf
-0.00999 Tc 0.009 Tw 10.5 0 0 10.5 62.028 146.7603 Tm
[(An additional adverse ef)20 (fect of many antipsychotics is)]TJ
-0.01401 Tc 0.01401 Tw -1 -1.2381 Td
[(prolongation of the corrected QT \(QT)70 (c\) interval. A medi-)]TJ
-0.02299 Tc 0.02299 Tw 24.57143 4.99637 Td
[(cation\325)55 (s ability to cause QT)70 (c interval prolongation is likely)]TJ
-0.02499 Tc 0.004 Tw 0 -1.2381 TD
(related to the degree to which it blocks the delayed rectifier)Tj
-0.02299 Tc 0.02299 Tw 0 -1.23809 TD
(potassium channel, which is responsible for ventricular re-)Tj
-0.02499 Tc 0 Tw 0 -1.2381 TD
(polarization.)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 6 0 0 6 358.8845 150.5222 Tm
(21)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0.007 Tw 10.5 0 0 10.5 367.0255 147.2222 Tm
(Delays in ventricular repolarization manifest)Tj
-0.02299 Tc 0.02299 Tw -5.47595 -1.2381 Td
[(as longer QT)70 (c intervals, a surrogate marker for torsades de)]TJ
-0.019 Tc 0.019 Tw 0 -1.23809 TD
(pointes \(TdP\).)Tj
ET
BT
/T1_2 1 Tf
-0.017 Tc 0 Tw 6 0 0 6 366.972 124.5223 Tm
(22)Tj
ET
BT
/T1_1 1 Tf
-0.019 Tc 0.019 Tw 10.5 0 0 10.5 375.3664 121.2222 Tm
(TdP is a polymorphic ventricular arrhyth)Tj
0 Tc 15.68256 0.00001 Td
(-)Tj
-0.02 Tc 0.02 Tw -21.95288 -1.2381 Td
(mia that may present as lightheadedness and syncope, and)Tj
0 Tc 0.019 Tw 0 -1.2381 TD
(in rare cases, can be fatal.)Tj
ET
BT
/T1_2 1 Tf
0.002 Tc 0 Tw 6 0 0 6 418.6405 98.5222 Tm
(23)Tj
ET
BT
/T1_1 1 Tf
-0.00011 Tc 10.5 0 0 10.5 427.462 95.2222 Tm
(A)Tj
0 Tc 0.019 Tw 0.99051 0 Td
[(QT)70 (c interval greater than)]TJ
-0.02499 Tc 0.011 Tw -12.22231 -1.23809 Td
(450 milliseconds for men and 470 milliseconds for women)Tj
0.021 Tw T*
[(indicates prolongation, with QT)70 (c intervals greater than 500)]TJ
0 Tc 0.03 Tw 0 -1.23809 TD
(milliseconds or a change from baseline that exceeds 60)Tj
-0.02499 Tc 0.013 Tw 0 -1.2381 TD
(milliseconds being considered clinically significant.)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 514.5276 46.5223 Tm
(24)Tj
ET
0 0 0 0 k
51.528 580 492 85 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
-0.03999 Tc 0.011 Tw 16.8 0 0 16 51.528 636.1398 Tm
[(T)165 (orsades de P)75 (ointes After Administration of Lo)34 (w-Dose Aripipraz)20 (ole)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 10.5 0 0 10 51.528 600.1398 Tm
(Sarah Nelson, Jonathan G Leung)Tj
ET
0 0 0 0 k
148.528 15.25 395 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0.013 Tw 10 0 0 10 260.1243 21.4116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 393.2493 22.9116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 406.4304 21.4116 Tm
[(2013 February)55 (, V)110 (olume 47    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 516.9602 22.9116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 10 0 0 10 530.1413 21.4116 Tm
[(e1)57 (1)]TJ
ET
0 0 0 0 k
51.028 15 79.5 13.5 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.02499 Tc 10 0 0 10 51.028 21.6616 Tm
(theannals.com)Tj
ET
0 0 0 0.14999 k
230.528 209.403 313 321.538 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
-0.024 Tc 7 0 0 7 242.528 510.5835 Tm
(OBJECTIVE)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 280.6865 510.5835 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 8.5 0 0 8.5 286.2077 510.5835 Tm
[(T)111 (o describe a case of torsades de pointes \(TdP\) in a patient treated)]TJ
-0.02499 Tc 0.011 Tw -5.13879 -1.26471 Td
(with aripiprazole.)Tj
ET
BT
/T1_6 1 Tf
-0.00011 Tc 0 Tw 7 0 0 7 242.528 486.0835 Tm
(C)Tj
0 Tc [-0.1 (ASE)-421 (SUMMAR)36 (Y)]TJ
ET
BT
/T1_6 1 Tf
10 0 0 10 300.3037 486.0835 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 0.017 Tw 8.5 0 0 8.5 306.1387 486.0835 Tm
[(A)-295 (42-year-old white male with schizophrenia, diabetes, hyper-)]TJ
-0.02499 Tc 0.009 Tw -7.48361 -1.2647 Td
(tension, and a history of stroke was admitted to the intensive care unit\ following 2)Tj
-0.017 Tc 0.002 Tw 0 -1.2647 TD
[(days of fever)55 (, diarrhea, and altered mental status. Following the resolution of his)]TJ
-0.015 Tc 0.132 Tw 0 -1.26471 TD
(acute illness, previous therapy with quetiapine 400 mg orally at bedtime\ was)Tj
-0.022 Tc 0.007 Tw 0 -1.2647 TD
(resumed for schizophrenia and presumed delirium. Quetiapine was disconti\nued)Tj
-0.024 Tc 0.009 Tw T*
(after 1 dose because of QT)Tj
-0.0242 Tc 11.42332 0 Td
(c)Tj
-0.024 Tc 0.73868 0 Td
[(interval prolongation. T)59.5 (wenty-three days later)]TJ
-0.0242 Tc 18.82122 0 Td
(,)Tj
-0.024 Tc 0.51663 0 Td
(with a)Tj
-0.034 Tc 0.019 Tw -31.49985 -1.26472 Td
[(baseline QT)111 (c interval of 414 milliseconds, aripiprazole 2.5 mg orally once daily wa\s)]TJ
-0.024 Tc 0.009 Tw T*
[(initiated. Following 5 days of aripiprazole therapy)74 (, the patient had a cardiac arrest)]TJ
-0.03999 Tc 0.019 Tw T*
[(due to TdP)129 (. Normal sinus rhythm was restored after 30 seconds of cardiopulmonary)]TJ
-0.01601 Tc 0.00101 Tw T*
(resuscitation, 1 shock of 200 Joules, and 4 g of intravenous magnesium s\ulfate.)Tj
-0.015 Tc 0.11099 Tw 0 -1.26471 TD
(Serial electrocardiographs obtained after aripiprazole discontinuation r\evealed)Tj
-0.03999 Tc 0.011 Tw 0 -1.2647 TD
(resolution of QT)Tj
-0.0401 Tc 6.38341 0 Td
(c)Tj
-0.03999 Tc 0.70887 0 Td
(interval prolongation. )Tj
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 7 0 0 7 242.528 354.0835 Tm
(DISCUSSION)Tj
ET
BT
/T1_6 1 Tf
10 0 0 10 286.083 354.0835 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
0.12199 Tw 8.5 0 0 8.5 292.8121 354.0835 Tm
(Aripiprazole is a second-generation antipsychotic that may be)Tj
-0.01601 Tc 0.01601 Tw -5.91578 -1.2647 Td
[(selected for patients with prolonged QT)111 (c intervals and at risk for TdP)128 (. Data from)]TJ
-0.019 Tc 0.019 Tw T*
[(trials indicate that aripiprazole has minimal ef)18 (fects on the QT)110 (c interval. However)55 (,)]TJ
-0.01199 Tc 0.01199 Tw T*
(in this case, aripiprazole was associated with TdP in a patient with min\imal risk)Tj
0 Tc 0.216 Tw 0 -1.26471 TD
(factors. The Naranjo probability scale was used to determine a probable)Tj
-0.02499 Tc 0.004 Tw 0 -1.2647 TD
(association between aripiprazole and the development of TdP)Tj
-0.02521 Tc 25.76781 0 Td
(.)Tj
-0.02499 Tc 0.50993 0 Td
[(T)111 (o our knowledge,)]TJ
0.011 Tw -26.27774 -1.26471 Td
(this is the first reported case of TdP associated with the use of aripip\razole.)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tc 0 Tw 7 0 0 7 242.528 275.8335 Tm
(CONCLUSIONS)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 293.1843 275.8335 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
-0.00999 Tc 0.00999 Tw 8.5 0 0 8.5 298.7772 275.8335 Tm
(Five days of low-dose aripiprazole therapy was associated with)Tj
-0.01601 Tc 0.01601 Tw -6.61755 -1.26471 Td
(the development of TdP in a man with minimal risk factors. Clinicians sh\ould be)Tj
-0.02499 Tc 0.011 Tw 0 -1.26471 TD
(aware of this potential adverse drug event with aripiprazole.)Tj
ET
BT
/T1_7 1 Tf
8.5 0 1.80673 8.5 242.528 239.3335 Tm
(Ann Pharmacother)Tj
ET
BT
/T1_0 1 Tf
0 Tw 8.5 0 0 8.5 314.109 239.3335 Tm
[(2013;47:e1)74 (1.)]TJ
0.011 Tw -8.4213 -1.76471 Td
(Published Online, 29 Jan 2013, )Tj
ET
BT
/T1_7 1 Tf
0 Tw 8.5 0 1.80673 8.5 356.8733 224.3335 Tm
(theannals.com)Tj
ET
BT
/T1_0 1 Tf
-0.0251 Tc 8.5 0 0 8.5 409.3752 224.3335 Tm
(,)Tj
-0.02499 Tc 0.011 Tw 0.51687 0 Td
(doi: 10.1345/aph.1R387)Tj
ET
0 0 0 1 K
2 w 
217.088 705.426 m
364.884 705.426 l
S
BT
/T1_8 1 Tf
0.075 Tc 18 0 0 18 230.1894 708.0727 Tm
[(C)-25 (ASE REPOR)90 (TS)]TJ
ET
1.472 704.329 223.001 16.046 re
f
0.5 w 
51.944 108.7499 m
287 108.7499 l
S
BT
/T1_0 1 Tf
-0.02499 Tc 8.5 0 0 8.5 51.944 96.4997 Tm
(Author information provided at end of text.)Tj
0 -1.8235 TD
[(\251)-264 (1967-2013 Harvey Whitney Books Co. All rights reserved. No)]TJ
0 -1.1176 TD
(part of this document may be reproduced or transmitted in any)Tj
T*
(form or by any means without prior written permission of Harvey)Tj
0 -1.1177 TD
(Whitney Books Co. For reprints of any article appearing in )Tj
ET
BT
/T1_7 1 Tf
0 Tw 8.5 0 1.80673 8.5 260.435 52.4996 Tm
(The)Tj
-24.2908 -1.1176 Td
(Annals)Tj
ET
BT
/T1_0 1 Tf
-0.0251 Tc 8.5 0 0 8.5 76.6504 42.9997 Tm
(,)Tj
-0.02499 Tc 0.011 Tw 0.5169 0 Td
(please contact 415sales@hwbooks.com)Tj
1 g
/T1_9 1 Tf
-0.278 Tc 0 Tw 1 0 0 1 -1000 1783 Tm
( )Tj
ET
BT
0 g
/GS2 gs
/T1_10 1 Tf
0 Tc 5 0 0 5 284.35733 11 Tm
( at UNIV CALGARY LIBRARY on May 25, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
24 0 obj
<</BaseFont/AXVMOU+GillSans-Bold/Encoding 21 0 R/FirstChar 32/FontDescriptor 23 0 R/LastChar 122/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 781 0 0 802 0 0 0 0 0 0 0 615 0 0 0 656 0 0 0 719 0 0 0 0 0 0 0 0 0 0 0 0 531 0 0 583 552 302 0 0 271 0 0 271 958 583 594 583 0 448 427 406 0 0 781 0 0 521]>>
endobj
44 0 obj
<</BaseFont/RQAHXW+GillSans/Encoding 41 0 R/FirstChar 32/FontDescriptor 43 0 R/LastChar 84/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 708 0 500 0 0 0 0 0 0 0 0 0 823 510 0 604 458 604]>>
endobj
48 0 obj
<</BaseFont/WQZJWI+Helvetica/Encoding 45 0 R/FirstChar 32/FontDescriptor 47 0 R/LastChar 32/Subtype/Type1/Type/Font/Widths[278]>>
endobj
45 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space]/Type/Encoding>>
endobj
47 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 34/FontBBox[-166 -224 1000 931]/FontFile3 46 0 R/FontName/WQZJWI+Helvetica/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
46 0 obj
<</Length 288/Length1 288/Subtype/Type1C>>stream
  WQZJWI+Helvetica   @¯ ¯¯¯¯˚:˚t˙|˙7
 ãã
 ãã   Ú   Ô   ı¨   ˇ Äà002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki      ¸u°¯üö˜)õôü˜°ñ¸}ö◊
„
_˜™˘
endstream
endobj
41 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 65/A 67/C 69/E 79/O/P 82/R/S/T]/Type/Encoding>>
endobj
43 0 obj
<</Ascent 716/CapHeight 682/Descent -230/Flags 32/FontBBox[-162 -230 1041 911]/FontFile3 42 0 R/FontName/RQAHXW+GillSans/ItalicAngle 0/StemH 0/StemV 89/Type/FontDescriptor/XHeight 728>>
endobj
42 0 obj
<</Length 850/Length1 850/Subtype/Type1C>>stream
  RQAHXW+GillSans   @¯ ¯¯¯¯˚6˚z˙•˙#
 ãã
 ãã   Ó   Í  ∑  & |ÖCopyright (c) 1990 Adobe Systems Incorporated. All Rights Reserved.Gill Sans is a trademark of The Monotype Corpration Plc.Gill Sans    $ " 4 &  3 1 0 5 
   M Ñ ÿ\òÔ¸≈ÇÂ¯úÂª˘$˘≤.DúE˚m˚1˚,˚d˚#˜˚Y˜îˆ‘§ÆŒˆY>7p>˚8˚ı˜-˜*˜˜˜0⁄”uZﬂú†v˜]„¯!wã˘/˜˛˘BF˚π˝BÔ·˜]˜∂Ê˚]Ô˚È¯¨˜˚ã˚h˚TÇ„¯†„≥Ê˜`Ê¯#˘´[WõW˚9D˚˚O˜ª{ã˚!eh[?HLÆÀY˚`ƒ«w’˜‹Ÿˆ˜m˚ªâã˜ª∏¨ π√{T≈˚*ã„˜h„˜b„÷Ì¯b˘>¸˝>¯ „˚æ˜h˜´„˚´˜b˜µ¸]†v˜º„˜jﬂÿÌ˜Yÿ˘>˝>Ì˜º¥Ω¥{˚ ÂÂ˚ ˜	\Ãz¢n∫W‡e M¥‘®¥∆ã⁄ã˜
5‘˚ãA7 Í±dKåRåmU"L˚ †v˜ª„˜g„—Ì˜{—˘>˝>Ì˜ªÒ˜2”ﬂˆ˜ G„˚)˚3˜‰¶UYG\dB˚˜AÇÂ¯úÂ∏¯ß∏˜È˚M˜!˚9˜s˜{˜˜:˜L˜R˚"˜4˚u˚q˚%˚5˚Q˜*˜˜˜,˜-˜˚˚*˚)˚˚˚-˚,˚˜˜)]†v¯Ê„˜ëÌ¯ﬂ˘>¸Œ3˜Ä¸ÊÌ¯Ê˜ÄÅï˘>ó˚âî˜ñó˜€ê¸∆ã€
‰Z 

yXO	˜™˘
endstream
endobj
21 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 45/hyphen 65/A 68/D 76/L 80/P 84/T 97/a 100/d/e/f 105/i 108/l/m/n/o/p 114/r/s/t 119/w 122/z]/Type/Encoding>>
endobj
23 0 obj
<</Ascent 716/CapHeight 682/Descent -221/Flags 262176/FontBBox[-177 -230 1167 929]/FontFile3 22 0 R/FontName/AXVMOU+GillSans-Bold/ItalicAngle 0/StemH 0/StemV 145/Type/FontDescriptor/XHeight 728>>
endobj
22 0 obj
<</Length 1769/Length1 1769/Subtype/Type1C>>stream
  AXVMOU+GillSans-Bold   A¯ ¯¯¯¯˚E˚zè˙5
 ãã
 ãã       1±  √ }ãîCopyright (c) 1990 Adobe Systems Incorporated. All Rights Reserved.Gill Sans is a trademark of The Monotype Corporation Plc.Gill Sans BoldGill Sans    5 P S T B E F  1 J O U " G N - X  % Q [ M    & m ≠ p `ô€\£/jÑ…"G`¸–†v¯¡˜˜ß˜>˘H˘>˝,˚˜ã¸¡˜>¯¡˜ãSÇ·˜«·∞˜/˜f˜/¯¡˜z˜E˚& ˚˚˚9˚1˚%˜,˜+Ò˜1√˜K˚/è&gSGTXÆ˜Û∂º ‘™O1˚^†v˜‚˜ÇwÀ˜%∞˜e¯a˚%¸a˜%˜[–‡´≠Ω¿¢§Ås±≥˜a™rñnãS[^+`â˚sÇÏ˜ûvæ·∞˜Í˜¯¯H£[`ïQ˚>R6˚+˜yóãHvp~`T\ûü\%Äü“t’˜œ¡Î˜.˚yçãæ´¨èû®…d ˚Ç·˜ºÏ¨˜'˜˜%¯ß˜siÄâÅ|Çî¢˜f<≤˚BHxfO˚
∫πÕ©≈ üi`à˚UO:u˚Q¬T’Ωπô±√fï¢|ª≤ƒù£≥˚t⁄usn~pqv°¶π¥ü·™HÇÏ3„˜±Ï˜hwÆ˜'˜Y˜%º¯†˘>˚%˚Öûddïa˚/)˚!˚Á%˜º±ò¨¥|f˜%º˚%˜pmrÄlG`√ﬂÁ∂¿‘•≠|†)Ç·˜◊·∞˜*˜_˜¯í˜#ZG^zQ0Sª›Ü˜ﬂ˜<í˚Í˚˚"&'˚!˚$Ù-˜6Ø‚ã»ﬁ˚‘˜{Àë∞∞ƒ√±eLë¸ë†v˜¶˜˜2˜ﬁ˜>˜M˜Cﬁ˘>˝>˜>˜¶˜˜1œ˜ÎËE˜˚0˚˚«Á¨vQXoo=<¸†v¯awÂ˜4¬˜4˚,˜%Ë˜d¯a˚%¸a˜%0B˘G_gg__Øg∑∑ØØ∑∑gØ_H†v¯	„3Ï«˜%˜A˜%ÿ˜a¯a˚%¸a˜%∏˜Ωƒ±¶ûØ¥™pJ˚≠˜%˜π˜+¥CP^uV]˚àÇˆ˜úÓŸ˜%¯¯a˚<˜%y˚U˚loÕ˚Z˚ﬁ_Î∏±ì†æÙwdoÑm^q®∏˜R˜<˜†v˜˜˜ù˜7ãwé˘õÿ¯o˘>˚Y˚ß˝>˜Hæ˜˜≈√˚˜K˚µ˜í˚fËÔ˜ù˚†v˜˛Ó˜˜Çw‹˜%Ë˜v¯a®»Æü∏õñäÜ±ÿ˜	Ëéueëo˚	6D˚tI(Õ˚˛˜%˜˛ÕÓ˜»†v¯	ÏÇw ˜%˜[˜%˜[˜%º˜d¯a˚%¸a˜%‹˜…µÆ±°±∂∏r@˚•˜%˜ªæ¨≤¶µ¿´fI˚¢˜%˜ºÙ@–"FVnFOÕkU´;npÜÄpºqqzrthã˜¯¡w◊˜>¯Ë˜˚Ú¯¡˚>˝>¯ú˜óv¯jwä˘£¯˜Ü˜˚è–˜c¯j˚(*˚í%˜í3$˚í*˜í˚(˜d¸jœ˚—†v˜9˜Ø˜ô˜Ω˜æ˚ô˚˜ô˜,ã˜¯D˜÷˜>˜·˜C÷˘>˝>˜Æ˜§˜˜$˜X˜O˚˜/˚ç˚˚˜˜5 (˚	'X˚˚?˚H˚ev˜qÏ˜õv∞È-Úƒ˜%˜[˜'ˆ˜^¯a˚%˝G˜%˜ëw≠∑¥˜ÂÏ˜(Ó˜-Ò˚Yb|ib0ßØ¢î™–≥X35_UDnqî†n˚ãÓ˜õÓû¯mµ¯a(˜j˚Å˚˛¯mÓ˚Ä˜Ä˜˛¸†v˘>w ˜%˜d˘>˚%˝>˜%Çî˘>î˚zî˜äó˜Ÿí¸∆îÓ
å
yXO	˜™˘
endstream
endobj
67 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
68 0 obj
<</OP false/OPM 0/op false>>
endobj
88 0 obj
<</A 89 0 R/Border[0 0 0]/Rect[243.612 9.0 285.357 16.0]/Subtype/Link/Type/Annot>>
endobj
89 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
63 0 obj
<</CreationDate(D:20130205160019Z)/Creator(QuarkXPress\(tm\) 6.5)/ModDate(D:20150525054051-07'00')/Producer(QuarkXPress\(tm\) 6.5)/Title(Layout 1)/XPressPrivate(%%DocumentProcessColors: Black\n%%EndComments)>>
endobj
xref
0 90
0000000000 65535 f
0000034662 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000001835 00000 n
0000053329 00000 n
0000053860 00000 n
0000053657 00000 n
0000050593 00000 n
0000025632 00000 n
0000026262 00000 n
0000026057 00000 n
0000013300 00000 n
0000023639 00000 n
0000024004 00000 n
0000023797 00000 n
0000013967 00000 n
0000092618 00000 n
0000093009 00000 n
0000092797 00000 n
0000089932 00000 n
0000019188 00000 n
0000019618 00000 n
0000019410 00000 n
0000014409 00000 n
0000023095 00000 n
0000023384 00000 n
0000023181 00000 n
0000014255 00000 n
0000059221 00000 n
0000059643 00000 n
0000059430 00000 n
0000050199 00000 n
0000051495 00000 n
0000051862 00000 n
0000051651 00000 n
0000051142 00000 n
0000091371 00000 n
0000091691 00000 n
0000091489 00000 n
0000090305 00000 n
0000090716 00000 n
0000091006 00000 n
0000090803 00000 n
0000090570 00000 n
0000077122 00000 n
0000077418 00000 n
0000077218 00000 n
0000076847 00000 n
0000015274 00000 n
0000015695 00000 n
0000015480 00000 n
0000014795 00000 n
0000001871 00000 n
0000001945 00000 n
0000002263 00000 n
0000002544 00000 n
0000002837 00000 n
0000000016 00000 n
0000095115 00000 n
0000000096 00000 n
0000078199 00000 n
0000078224 00000 n
0000094857 00000 n
0000094915 00000 n
0000015185 00000 n
0000062973 00000 n
0000062998 00000 n
0000077941 00000 n
0000077999 00000 n
0000034961 00000 n
0000034986 00000 n
0000062715 00000 n
0000062773 00000 n
0000003094 00000 n
0000003119 00000 n
0000034703 00000 n
0000034761 00000 n
0000034806 00000 n
0000034905 00000 n
0000062818 00000 n
0000062917 00000 n
0000078044 00000 n
0000078143 00000 n
0000094960 00000 n
0000095059 00000 n
trailer
<</Size 90/Root 62 0 R/Info 63 0 R/ID[<E7209500DAC2DB2FD049C41E219B9410><73BE7F68D21DB2110A00640810000000>]>>
startxref
95341
%%EOF
